University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations

2019

Molecular Roles Of Regulatory Proteins In NTerminal Protein Acetylation
Leah Gottlieb
University of Pennsylvania, gottlieb.leah@gmail.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Biochemistry Commons
Recommended Citation
Gottlieb, Leah, "Molecular Roles Of Regulatory Proteins In N-Terminal Protein Acetylation" (2019). Publicly Accessible Penn
Dissertations. 3251.
https://repository.upenn.edu/edissertations/3251

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3251
For more information, please contact repository@pobox.upenn.edu.

Molecular Roles Of Regulatory Proteins In N-Terminal Protein
Acetylation
Abstract

The irreversible and predominately co-translational N-terminal acetylation of proteins is an essential process
used in the regulation of protein functions including folding, targeting, protein-protein interactions, and
degradation. The seven conserved metazoan N-terminal acetyltransferase (NAT) enzymes (NatA-NatF and
NatH) modify ~80% of human proteins. As an essential protein mark involved in human development and
health, aberrant NAT activity contributes to several developmental disorders and is linked to human disease,
including cancer and some neurodegenerative disorders.
NAT enzymes minimally contain a catalytic subunit and up to two auxiliary subunits for enzymatic activity,
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activity. Finally, we report preliminary results on the interplay between HYPK and a putative interacting
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development of therapeutics for the exploitation of NAT regulatory mechanisms and targeting of these
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ABSTRACT
MOLECULAR ROLES OF REGULATORY PROTEINS IN N-TERMINAL PROTEIN
ACETYLATION
Leah Gottlieb
Ronen Marmorstein

The irreversible and predominately co-translational N-terminal acetylation of
proteins is an essential process used in the regulation of protein functions including folding,
targeting, protein-protein interactions, and degradation. The seven conserved metazoan Nterminal acetyltransferase (NAT) enzymes (NatA-NatF and NatH) modify ~80% of human
proteins. As an essential protein mark involved in human development and health, aberrant
NAT activity contributes to several developmental disorders and is linked to human
disease, including cancer and some neurodegenerative disorders.
NAT enzymes minimally contain a catalytic subunit and up to two auxiliary
subunits for enzymatic activity, selectivity, and ribosomal targeting.

Current NAT

biochemical and structural information primarily describes the basis for monomeric NAT
activity. Initial insights into regulatory subunit influence on NAT activity comes from the
NatA crystal structure where regulatory subunit (Naa15p) reconfigures the active site of
the catalytic subunit (Naa10p) for substrate-specific N-terminal acetylation.

This,

however, fails to describe the influence of Naa38p and HYPK in NatC and metazoan NatAmediated activity, respectively.
In order to understand the basis for NAT regulatory mechanisms and the
implications of aberrant NAT activity in human disease, we focused on the human
NatA/HYPK and S. cerevisiae NatC complexes. We determined X-ray crystal structures
of NatA and NatA/HYPK complexes and carried out associated biochemical, enzymatic,
vi

and structural studies.

We demonstrate that human HYPK harbors intrinsic NatA

inhibitory activity through a bipartite structure, presumably to more effectively regulate
cognate NatA activity. We also demonstrate that the NatA–HYPK interaction reduces
Naa50 targeting to NatA, likely limiting ribosomal localization of Naa50 in vivo. We
evaluated the effects of human NatA disease-associated missense mutations on its function
and evaluated the contribution to either NatA activity or thermal stability. We showed that
binding

of

the

small

Naa38p

subunit

is

critical

for

NatC

complex

(Naa30p/Naa35p/Naa38p) activity. Finally, we report preliminary results on the interplay
between HYPK and a putative interacting partner and NatA substrate, Huntingtin (Htt).
These studies provide novel mechanistic insights into the activity of NAT proteins
and lay the groundwork for development of therapeutics for the exploitation of NAT
regulatory mechanisms and targeting of these specialized acetyltransferases for therapy.

vii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ............................................................................................ iii
ABSTRACT ...................................................................................................................... vi
LIST OF TABLES .......................................................................................................... xii
LIST OF FIGURES ....................................................................................................... xiii
CHAPTER 1 N-terminal Acetylation: A Mark of the Beginning................................ 1
1.1 Protein Regulation .................................................................................................... 2
1.2 Modification of Proteins........................................................................................... 4
1.2 Protein Acetylation ................................................................................................... 5
1.3 The N-terminal acetyltransferase (NAT) Enzyme Family.................................... 9
1.4 Implications of N-terminal Acetylation in Human Development and Disease . 15
1.5 Dissertation Objectives .......................................................................................... 17
CHAPTER 2 Function and Structure of the Human NatA ....................................... 19
2.1 Introduction and Summary of Conclusions ......................................................... 20
2.2 Results ...................................................................................................................... 21
2.2.1 Overall Crystal Structure of the Human NatA Complex..................................... 21
2.2.2 Implications of the Metazoan-Specific Naa15 C-terminal Domain .................... 26
2.3 Discussion and Future Studies .............................................................................. 28
2.4 Methods ................................................................................................................... 31
2.4.1 Construction of Baculoviruses ............................................................................ 31
2.4.2 Expression and Purification of 6xHis-tagged Human NatA Constructs............. 31
2.4.3 Binary Human NatA Complex Crystallization and Structure Determination..... 32
2.4.4 Radioactive Acetyltransferase Assays ................................................................. 34
2.4.5 Differential Scanning Calorimetry (DSC) .......................................................... 35
2.4.6 Analytical Ultracentrifugation (AUC) ................................................................ 35
CHAPTER 3 The Huntingtin-Interacting Protein HYPK Inhibits Human NatA
Complex Activity............................................................................................................. 37
3.1 Introduction and Summary of Conclusions ......................................................... 38
viii

3.2 Results ...................................................................................................................... 40
3.2.1 HYPK Exhibits Specific Intrinsic Inhibitory Activity Towards Human NatA ..... 40
3.2.2 Overall Crystal Structure of the Ternary Human NatA/HYPK Complex ........... 41
3.2.3 HYPK Increases NatA Thermal Stability and Deletion and Mutational Analysis is
Consistent with a Bipartite Mode of NatA Inhibition .................................................. 46
3.2.4 Mechanism of HYPK-Mediated Human NatA Inhibition .................................... 48
3.2.5 HYPK Blocks Human Naa50 Recruitment to the Human NatA Complex in vitro
...................................................................................................................................... 52
3.3 Discussion and Future Directions ......................................................................... 54
3.4 Methods ................................................................................................................... 57
3.4.1 Construction of E. coli Expression Vectors ........................................................ 57
3.4.2 Construction of Baculoviruses ............................................................................ 57
3.4.3 Expression and Purification of 6xHis-tagged Human NatA Constructs............. 58
3.4.4 Expression and Purification of MBP-tagged HYPK Constructs ........................ 58
3.4.5 Expression and Purification of Human NatA/HYPK .......................................... 59
3.4.6 Human NatA/HYPK Crystallization and Structure Determination .................... 60
3.4.7 Expression and Purification of Other NAT and HAT Enzymes .......................... 61
3.4.8 hNatA Radioactive Acetyltransferase Assays ..................................................... 66
3.4.9 HAT and NAT Radioactive Acetyltransferase Assays ......................................... 67
3.4.10 IC50 Assays ........................................................................................................ 68
3.4.11 Generation of a Noncompetitive Tight-Binding (Morrison) Fit ....................... 68
3.4.12 Differential Scanning Calorimetry (DSC) ........................................................ 69
3.4.13 MBP- and GST- Pull-Down Assays .................................................................. 69
CHAPTER 4 Expanding the Biochemical Characterization of Naa10 and Naa15
Missense Mutations......................................................................................................... 71
4.1 Introduction and Summary of Conclusions ......................................................... 72
4.2 Results ...................................................................................................................... 73
4.2.1 Functional Characterization of Human NatA Missense Mutations – Naa10 ..... 73
4.2.2 Functional Characterization of Human NatA Missense Mutations – Naa15 ..... 77
4.3 Discussion and Future Directions ......................................................................... 82
4.4 Methods ................................................................................................................... 85
4.4.1 Construction of E. coli Expression Vectors ........................................................ 85
4.4.2 Construction of Baculoviruses ............................................................................ 85
ix

4.4.3 Expression and Purification of 6xHis-tagged Human NatA Mutant Constructs 86
4.4.4 Expression and Purification of MBP-tagged HYPK Constructs ........................ 86
4.4.5 hNatA Radioactive Acetyltransferase Assays ..................................................... 86
4.4.6 Thermal Stability Assays ..................................................................................... 87
CHAPTER 5 Naa38p Enhances NatC Complex Activity .......................................... 88
5.1 Introduction and Summary of Conclusions ......................................................... 89
5.2 Results ...................................................................................................................... 91
5.2.1 NatC Requires Naa38p for Robust Enzymatic Activity ....................................... 91
5.2.2 Inositol Hexaphosphate (IP6) and Naa38p are Required for Maximal NatC activity
...................................................................................................................................... 91
5.2.3 Binary and Ternary NatC Crystallization Trials ................................................ 93
5.3 Discussion and Future Directions ......................................................................... 95
5.4 Methods ................................................................................................................... 97
5.4.1 Construction of E. coli Expression Vectors ........................................................ 97
5.4.2 Expression and Purification of S. cerevisiae Binary NatC Complex
(ScNaa30p/ScNaa35p) ................................................................................................. 97
5.4.3 Binary NatC Complex Crystallization ................................................................ 98
5.4.4 Expression and Purification of S. cerevisiae Ternary NatC Complex
(Naa30p/Naa35p/Naa38p) ........................................................................................... 98
5.4.5 Ternary NatC Complex Crystallization .............................................................. 99
5.4.6 Negative Stain Electron Microscopy................................................................. 100
5.4.7 Radioactive Acetyltransferase Assays ............................................................... 100
5.4.8 Thermal Stability Assays ................................................................................... 101
5.4.8 Limited Proteolysis of ScNatC Complexes........................................................ 102
Appendix: Molecular Role of HYPK and NatA-Mediated Co-translational Nterminal Acetylation in Huntingtin (Htt) Aggregation.............................................. 103
A1 Introduction and Summary of Conclusions ....................................................... 104
A2 Results .................................................................................................................... 107
A2.1 Development of Htt PolyQ N-terminal Fragment Constructs for in vitro Studies
.................................................................................................................................... 107
A2.2 Monitoring HttQ44 Aggregation ....................................................................... 109
A2.3 HYPK Does Not Bind Monomeric HttQ44 Directly in vitro ............................. 111
A2.4 N-terminal Acetylation Promotes Helical Htt Peptide Propensity .................... 112
x

A2.4 N-terminal Acetylation Increases Htt Aggregation Propensity ......................... 113
A3 Discussion and Future Directions ....................................................................... 115
A4 Methods ................................................................................................................. 118
A4.1 Construction of E. coli Expression Vectors ....................................................... 118
A4.2 Expression and purification of Htt proteins ...................................................... 118
A4.3 Western Blot Analysis ........................................................................................ 119
A4.4 Edman Degradation .......................................................................................... 119
A4.5 Radioactive acetylation of Htt Peptide .............................................................. 120
A4.6 Expression and purification of N-terminally Acetylated HttQ44-(GS)4-SUMO
protein ........................................................................................................................ 120
A4.7 Matrix-Assisted Laser Desorption/Ionization (MALDI).................................... 121
A4.8 Sample Preparation and Transmission Electron Microscopy (TEM) of Htt
Aggregates ................................................................................................................. 121
A4.9 Thioflavin-T Fluorescence Aggregation Assay ................................................. 122
A4.10 Pull-Down Assays ............................................................................................ 122
A4.11 N-terminal Htt Peptide Synthesis .................................................................... 123
A4.12 Circular Dichroism (CD) Spectroscopy .......................................................... 123
A4.13 Crystallization Screening of NatA/HYPK with CoA/Peptide .......................... 124
References ...................................................................................................................... 125

xi

LIST OF TABLES
Table 1. hNatA Complex Data Collection and Refinement Statistics ..................................... 22
Table 2. Human NATs as NAT Substrates ................................................................................ 29
Table 3. Human Naa15 Truncation Constructs ........................................................................ 31
Table 4. hNatA/HYPK Complex Data Collection and Refinement Statistics ........................ 43
Table 5. Catalytic Parameters for Wild-Type hNatA and hNatA/ HYPK Complexes ......... 49
Table 6. Mutant HYPK Constructs ............................................................................................ 57
Table 7. Catalytic Parameters of Naa10 Mutant NatA Complexes......................................... 75
Table 8. NatA Missense Mutant Constructs .............................................................................. 85

xii

LIST OF FIGURES
Figure 1. Diagram of Co-Translational Protein Processing....................................................... 4
Figure 2. Acetylation of Proteins .................................................................................................. 5
Figure 3. Cellular Functions of N-terminal Acetylation............................................................. 7
Figure 4. Ac/N-End Rule Pathway ............................................................................................... 8
Figure 5. The Human N-terminal Acetylome .............................................................................. 9
Figure 6. The Metazoan NAT Family ........................................................................................ 10
Figure 7. GNAT Fold Topology .................................................................................................. 11
Figure 8. The NAT Active Site Occludes Lysine Side Chain Substrates ................................ 12
Figure 9. NAT Catalytic Strategies ............................................................................................ 13
Figure 10. Fission Yeast Naa10p/Naa15p (NatA) Crystal Structure ...................................... 14
Figure 11. Sedimentation Equilibrium of human NatA ........................................................... 21
Figure 12. Overall Structure of hNatA ...................................................................................... 22
Figure 13. IP6 Fo-Fc Map ............................................................................................................. 24
Figure 14. Alignment of Naa15 Homologues ............................................................................. 25
Figure 15. Alignment of Naa10 Homologues ............................................................................. 26
Figure 16. C-terminal Truncation of Naa15 Abrogates NatA Binary Complex Formation 27
Figure 17. Specific Binding and Inhibition by HYPK to hNatA ............................................. 41
Figure 18. Structure of HYPK-Bound hNatA ........................................................................... 42
Figure 19. Molecular and Thermodynamic Details of HYPK-hNatA Interaction ................ 47
Figure 20. Mechanism of NatA Inhibition ................................................................................. 49
Figure 21. HYPK Binding Reduces hNatA Capacity to Bind Naa50 ...................................... 53
Figure 22 Annotated Structure of NatA/HYPK ........................................................................ 73
Figure 23. Comparison of Activity and Thermal Stability of NatA Complex Missense
Mutants ......................................................................................................................................... 74
Figure 24. Naa10 Mutant Enzyme Kinetics ............................................................................... 75
Figure 25. IP6 Partially Rescues Naa15K450E Complex Function ............................................. 79
Figure 26. Naa38p Enhances NatC Enzymatic Activity ........................................................... 91
Figure 27. IP6 Interacts with the NatC Complex ...................................................................... 92
Figure 28. NatC Complexes Crystals ......................................................................................... 94
Figure 29. Negative Stain EM of NatC Complexes ................................................................... 96
Figure 30. HttQ44-SUMO (HttQ44) Recombinant Protein ................................................... 107
Figure 31. Htt N-terminal Acetylation ..................................................................................... 109
Figure 32. Monitoring Unmodified HttQ44 Aggregation ...................................................... 110
Figure 33. MBP-HYPK Does Not Pull-Down Monomeric HttQ44 ....................................... 112
Figure 34. N-terminal Acetylation of Htt Peptides Promote a-Helicity ............................... 113
Figure 35. N-terminal Aceylation Enhances HttQ25 Aggregation Propensity .................... 114

xiii

CHAPTER 1
N-terminal Acetylation: A Mark of the Beginning

1

1.1 Protein Regulation
A recent estimate of protein-coding genes approximates that number to be around
19,000-20,000 (Ezkurdia et al. 2014, Ponomarenko et al. 2016, Steward et al. 2017).
Together, these proteins are charged with sensing environmental changes, managing cell
replication, maintaining homeostasis, and identifying as well as defending the cell from
threats (Liu et al. 2013, Sun et al. 2014, Warnhoff et al. 2014, Verdin and Ott 2015, Rong
et al. 2016, Wang et al. 2017, Rape 2018, Xiang et al. 2018). Regulation of these proteins
requires control at every level within the cell in response to both internal and external
stimuli.
Proteins are complex molecules that require explicit instructions about when,
where, and how they are specified to carry out their individual function. Although there is
often overlap between the two, this is usually accomplished through using one of two
different mechanisms, or even using both: on a “global”/cellular level or on a local/proteinspecific level.
Global regulation of protein activity can arise from events of extrinsic control, such
as via non-specific degradation – such as autophagy, mitophagy, etc. – or via
transcriptional regulation and epigenetic control, directing when the cell will express a
protein of interest (Gilbert et al. 2013, Martin et al. 2015, Verdin and Ott 2015). Moreover,
intrinsic control of a protein or enzyme can be tissue- or cell-specific, calling for the
generation of a protein’s isoform (Kelemen et al. 2013, Varland et al. 2018).
The local control of protein activity can arise from a plethora of mechanisms, such
as protein modifications, proteolysis, protein-protein interactions (PPIs) with binding
partners, specific localization, small-molecule binding, and targeted degradation (Uetz et
al. 2000, Behnia et al. 2004, Setty et al. 2004, Tsuchiya et al. 2014, Aksnes et al. 2016,
2

Grasso et al. 2016, Hirano et al. 2016, Liu et al. 2016, Montgomery et al. 2016). These
changes can induce cascades, ranging in a variety of potential short- and/or long-lived
changes: altered substrate specificity, induction of novel ligand- or protein-binding
interactions, aberrant enzymatic activity levels – including complete inhibition– or even
the targeting of a particular protein for degradation.
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1.2 Modification of Proteins
Following protein synthesis, proteins can undergo a variety of processing events,
not limited to modification of individual side chains and proteolysis. Throughout the years,
numerous post-translational modifications have been identified including, but not limited
to: acetylation (ε-amino and α-amino), glycosylation, methylation, phosphorylation,
ubiquitination, amongst others (Shortreed et al. 2015).
As a protein exits the ribosome, it may be co-translationally processed and/or
modified. Due to the unique chemistry of the α-amino moiety, the N-terminus can act as
an exclusive handle for interactions and as a singular site for the specific incorporation of
a singular label. Several possible chemistries are available: methionine excision, (Nterminal)

arginylation,

acetylation,

formylation,

methylation,

myristylation,

palmitoylation, ubiquitination (Figure 1) (Giglione et al. 2015, Varland et al. 2015).

Figure 1. Diagram of Co-Translational Protein Processing
Modifications found in different systems. Figure taken from (Giglione et al. 2015).
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1.2 Protein Acetylation
Of all of the modifications that have been identified, acetylation stands out as one
of the most common. Acetylation broadens protein function by allowing for the dynamic
regulation of cellular processes in response to stimuli. During this reaction, an acetyl group
is transferred from acetyl coenzyme A (acetyl-CoA) to the ε-nitrogen of a lysine residue or
onto the N-terminal α-amino group (Figure 2) (Arnesen 2011, Friedmann and Marmorstein
2013). These reactions are catalyzed by either lysine acetyltransferases (KATs) or Nterminal acetyltransferases (NATs), respectively. Unlike the NATs, the implications of
KAT activity have been thoroughly described. Notably, the reversible post- translational
acetylation and deacetylation of lysine residues via lysine deacetylases (KDACS) on
histones contributes to gene expression and silencing, respectively.

Figure 2. Acetylation of Proteins
Reaction overview of (a) Lysine (ε-amino) acetylation, (B) N-terminal acetylation,
(C) annotation of the acetyl coenzyme A co-factor.
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Owing to the importance of histone acetylation, aberrant activities of these enzymes
have been connected with both metabolic disorders and cancer (Choudhary et al. 2014,
Marmorstein and Zhou 2014). In fact, thousands of non-histone proteins in prokaryotic
and eukaryotic cells are also acetylated on their side chain lysine residues to mediate
diverse biological processes in and out of the nucleus (Das and Kundu 2005).
Thorough studies of the KATs have provided insight into the molecular basis for
enzymatic activity. Structural and enzymatic activity studies have shown that the catalytic
activity occurs in a highly conserved core region and that KAT activity can be modulated
by several mechanisms with contributions from the divergent protein segments flanking
this core region, autoacetylation – such as with p300 – and/or the presence of necessary
protein binding partners – such as with Rtt109 (Wang et al. 2008, Marmorstein and Zhou
2014). In the case of p300, autoacetylation is necessary for enhanced acetyltransferase
activity. On the other hand, Rtt109 exhibits robust catalytic activity only when it is bound
to the histone chaperones, Vps75 or Asf1. Substrate specificity of Rtt109 can also be
modulated by the divergent flanking regions in the catalytic subunit and/or by associated
protein subunits.
Initially, protein N-terminal acetylation was believed to play a role in the
stabilization of proteins and, in turn, block their degradation (Persson et al. 1985). More
recent studies have found that not only does N-terminal acetylation play a more nuanced
role in protein degradation, it also can impact a variety of protein functions and, as a result,
numerous cellular processes (Figure 3) (Nguyen, Mun, et al. 2018, Ree et al. 2018). As a
hydrophobic moiety, the N-terminal acetylation of proteins can impact their half-lives,
folding, ability to form complexes, and targeting to membranes.
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Figure 3. Cellular Functions of N-terminal Acetylation
The modification of a protein’s N-terminus can influence its (A) degradation (B)
folding (C) interactions with other proteins (D) membrane localization. Figure taken
from (Ree et al. 2018)

N-terminal acetylation plays a role as a mark of an N-degron in the Ac/N-end rule
pathway, causing some N-terminally acetylated proteins to be targeted for degradation
(Figure 4) (Nguyen, Mun, et al. 2018). N-terminal acetylation has been found to influence
cellular morphology and phosphorylation levels. For example, insufficient N-terminal
acetylation of both tropomyosin and actin inhibits tropomyosin binding to actin as well as
the interactions between actin and other cytoskeletal proteins in yeast (Polevoda et al.
2003). Additionally, knockdown of NatB in yeast leads to the elevation of phosphorylation
levels at ~2300 sites by a mechanism that has not yet been elucidated (Helbig et al. 2010).
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Figure 4. Ac/N-End Rule Pathway
S. cerevisiae Ac/N-end rule pathway defining substrates involved in N-terminal
acetylation-mediated targeted protein degradation. Figure taken from (Nguyen, Mun,
et al. 2018)
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1.3 The N-terminal acetyltransferase (NAT) Enzyme Family
The co- and post-translational N-terminal acetylation of protein substrates takes
place on ~80% and 60% of the human and yeast proteome, respectively (Figure 5). The
highly conserved N-terminal acetyltransferases (NATs) use an ordered BiBi reaction to
transfer an acetyl moiety (H3CCO-) from acetyl coenzyme A to the positively-charged αamino group of the N-terminus of the protein substrates (Arnesen et al. 2009, Evjenth et
al. 2009, Van Damme, Hole, et al. 2011, Liszczak et al. 2013). Our understanding, to date,
is that the process is irreversible: an NDAC (N-terminal deacetylase) has not yet been
identified.

Figure 5. The Human N-terminal Acetylome
(A) Representation of human N-terminal (Nt-) acetylome predominance. Grouping
of substrate type based on:
(B) NAT complex identity
(C) Identity of the two initial N-terminal amino acids. Figure taken from (Ree et al.
2018).

A NAT enzyme consists minimally of a catalytic subunit – such as with NatD,
NatF, NatG, and NatH – and can contain an auxiliary subunit that serves as a ribosomal
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anchor for co-translational activity – such as with NatA and NatB – and an additional
subunit – such as NatA/HYPK, NatE, and NatC (Aksnes et al. 2016, Drazic et al. 2018,
Goris et al. 2018, Ree et al. 2018). Together, the substrate specificity and subunit
composition of a NAT enzyme distinguish each of these enzymes from one another (Figure
6). Substrate selectivity can range from being relatively promiscuous such as with NatA,
which acetylates proteins whose N-termini contain Ser-, Ala-, Thr-, Val-, or Gly- residues;
or as exclusive as NatD, which only acetylates the N-terminal serine residue of histones
H2A and H4.

Figure 6. The Metazoan NAT Family
Subunit composition and substrate specificities of the (A) major NATs depicted bound to the
ribosome via their respective ribosomal anchors, (B) the specialized NATs. Figure was
adapted from (Aksnes et al. 2016).

Over the past decade, biochemical and structural studies of almost all of the NATs,
except NatC, have been reported, including a more recent study describing the interaction
between a translating S. cerevisiae ribosome and the ternary NatA/Naa50 complex
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(Liszczak et al. 2013, Liszczak and Marmorstein 2013, Magin et al. 2015, Stove et al. 2016,
Hong et al. 2017, Magin et al. 2017, Neri et al. 2017, Weyer et al. 2017, Goris et al. 2018,
Gottlieb and Marmorstein 2018, Knorr et al. 2018). All of the NAT catalytic subunits
feature a General control non-repressible 5 (GCN5)-related N-acetyltransferase fold (Salah
Ud-Din et al. 2016) and an acetyl coenzyme A binding motif, Q/RxxGxG/A. The topology
of this fold consists of four α-helices and 7 β-strands, where the “P-loop” makes
interactions with acetyl coenzyme A (Figure 7).

Figure 7. GNAT Fold Topology
Conserved secondary structure motifs colored green, blue, red, and magenta, while
the secondary structural elements that are sometimes absent in GNATs is indicated
in wheat. Figure from (Salah Ud-Din et al. 2016).

These studies have also found that, contrary to some reports (Shin et al. 2014, Yoon
et al. 2014, Magin et al. 2016), NATs are unable to acetylate lysine side chains and they
discern their N-terminal substrates from lysine substrates using an occlusion method. A
structural loop, the β6-β7 loop, permits only the insertion of an N-terminal polypeptide
chain, while KATs, such as a GCN5, feature a large cleft that can accommodate the close
interaction of a lysine side chain from an extended peptide chain for acetylation (Figure 8)
(Rojas et al. 1999, Liszczak et al. 2011).
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Figure 8. The NAT Active Site Occludes Lysine Side Chain Substrates
Surface representations of substrate-bound (shown in black sticks)
(A) Naa10 (pink: 4KVM) with the β6-β7 loop colored in purple
(B) GCN5. (cyan: 1QSN)

Although the NAT catalytic subunits all feature a GNAT fold, they do not all use
the same chemical mechanism of catalysis (Figure 9). The archaeal NAT, Sulfolobus
solfataricus (ss)NAT, was found to be able to target both NatA-like substrates and MetN-termini. Consistent with this, it uses two general bases and two strategies to Nterminally acetylate its substrates: an ordered water and 1) ssNAT-H137 and ssNAT-E176;
2) ssNAT- E84 and ssNAT-E176, respectively (Figure 9A and B) (Liszczak and
Marmorstein 2013). Naa50, similar to GCN5, uses a structural water to act in conjunction
with Naa50-Y73 and Naa50-H112 and modify its Met- N-terminal substrates (Figure 9C)
(Liszczak et al. 2011). Naa60 and Naa40 both resemble Naa50, Naa60 using Naa60-Y97
and Naa60-H138 in conjunction with an ordered water for catalysis, and Naa40 using
Naa40-Y85 and Naa40-E139 (Figure 9D and E) (Magin et al. 2015, Stove et al. 2016).
With Naa10, Naa10-E24 was initially identified to be a catalytic residue (Figure 9F).
However, its distance, similar to the distance of the catalytic residues in Naa50, is likely
too far to participate directly in catalysis. Instead, tyrosine residues laying on top may be
a candidate as one of Naa10’s catalytic residues in the NatA complex (Liszczak et al. 2013).
Although a structure of NatB has been reported, a general base has not yet been identified
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and, interestingly, the mutation of the corresponding Naa10-E24 residue in Naa20 (E25)
to alanine resulted in an unexpected increase in enzymatic activity (Hong et al. 2017).

Figure 9. NAT Catalytic Strategies
Cartoon representation of NAT catalytic subunits with substrate(s) (depicted in black
sticks) and ordered-water (red sphere, A-D).
Catalytic residues identified in ssNatA shown with acetyl-CoA (4LX9) (A) strategy
1 and (B) strategy 2, (C) Naa50 with CoA (3TFY), (D) Naa60 with CoA (5ICW), (E)
Naa40 with CoA and H2A/H4 peptide (4U9W) and (F) Naa10 with bisubstrate
inhibitor (4KVM). Associated PDB ascension codes indicated in parenthesis.
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While N-terminal mechanism of action of the catalytic subunits of the NATs is
generally understood, the molecular basis for the influence of these regulatory subunits has
only been thoroughly described by one model – NatA (Figure 10A). Alone, the catalytic
subunit, Naa10p, is capable of acetylating the non-canonical acidic Glu- and Asp- Nterminal substrates of β- and γ-actin (Van Damme, Evjenth, et al. 2011, Liszczak et al.
2013). However, the large regulatory subunit, Naa15p, wraps around Naa10p, inducing a
conformational change and allowing for acetylation of its canonical small hydrophobic
substrates (Figure 10B). With this conformational change, the side chains of Naa10pLeu22 and Tyr26 move into the active site from a surface-exposed position, while the side
chain of Naa10p-Glu24, a catalytic residue, shifts approximately 5 Å for catalysisenhanced substrate binding selectivity. It appears, however, that this model is incomplete,
as it did not describe the influence of the metazoan-specific regulatory subunit, Huntingtin
(Htt) Yeast Two-Hybrid Protein K (HYPK) (Arnesen et al. 2010).

Figure 10. Fission Yeast Naa10p/Naa15p (NatA) Crystal Structure
(A) Full Naa10p/Naa15p structure
(B) Naa15p binding induces a conformational change in Naa10p. Figure adapted
from (Liszczak et al. 2013). PDB: 4KVO
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1.4 Implications of N-terminal Acetylation in Human Development and Disease
It is no surprise that when the far-reaching effects of N-terminal acetylation go
awry, their influence on cellular processes can turn into destructive human disorders and
diseases. After the initial discovery of the fatal X-linked disorder, Ogden Syndrome, other
developmental disorders associated with NAT activity have been identified (Rope et al.
2011). Developmental disorders that have been described thus far are Naa10-associated or
NatA-associated and primarily appear to result from decreased enzymatic activity.
Although one NatC-related developmental disorder has been identified, arising from the
deletion of the small auxiliary subunit, Naa38p, the disorder has not yet been characterized
(Zhao et al. 2016).

Individuals presenting with NAT-type developmental disorders

typically display dysmorphic abnormalities, congenital cardiac abnormalities, delayed
intellectual and motor abilities, autistic traits, hearing disabilities, amongst others (Rope et
al. 2011, Naa et al. 2014, Van Damme et al. 2014, Casey et al. 2015, Dorfel and Lyon 2015,
Myklebust et al. 2015, Popp et al. 2015, Zhao et al. 2016, Dorfel et al. 2017, Sidhu et al.
2017, Stessman et al. 2017, Cheng, Dharmadhikari, et al. 2018, McTiernan et al. 2018,
Stove et al. 2018, Takata et al. 2018, Zhao et al. 2018).
NAT activity may also be linked to neurodegenerative diseases. NatB N-terminally
acetylates the Parkinson’s Disease (PD)-associated α-Synuclein, potentially serving a
protective role in PD (Kang et al. 2012, Fernandez and Lucas 2018a, Fernandez and Lucas
2018b, Lima et al. 2018). Similarly, Huntingtin (Htt) , which was recently found to be Nterminally acetylated, likely by NatA, interacts with HYPK, a NatA regulatory subunit
(Faber et al. 1998, Huang et al. 2015). Moreover, NatA knockdown was also found to
reduce a prion phenotype in yeast (Pezza et al. 2009).
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In

addition

to

the

neurological

disorders,

both

developmental

and

neurodegenerative, numerous connections have been made between N-terminal
acetyltransferases and cancer. Unfortunately, these studies have not yet identified a direct
link between N-terminal acetylation and cancer (Fluge et al. 2002, Lim et al. 2006,
Ametzazurra et al. 2008, Ren et al. 2008, Liu et al. 2009, Yu, Gong, et al. 2009, Yu, Ma,
et al. 2009, Kuo and Hung 2010, Kalvik and Arnesen 2013, Zhang et al. 2013, Naa et al.
2014, Pavlou and Kirmizis 2016, Zeng et al. 2016, Ju et al. 2017, Neri et al. 2017, Chien
et al. 2018, Zhang et al. 2018).
The specificity of the NATs makes them an attractive drug candidate. Multiple
studies have used a bisubstrate inhibitor, consisting of a non-hydrolyzable CoA moiety
fused to a cognate peptide substrate (Foyn et al. 2013, Liszczak et al. 2013, Stove et al.
2016, Hong et al. 2017, Weyer et al. 2017). In fact, structural studies have benefited from
the use of bisubstrate inhibitors. Taken together, the structural information gleamed from
the bisubstrate inhibitor-bound structures will likely lay the groundwork for the
development of drug-like molecules to target NAT-related diseases.
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1.5 Dissertation Objectives
While the emergent N-terminal acetyltransferase class of enzymes has been studied
in terms of their biochemical, enzymatic, and structural features, an understanding of
overarching regulatory mechanisms dictating their activity remains minimal. due to the
inherent variability of the NATs, I have been interested in understanding the basis for these
differences and how these variations may arise from their respective regulatory subunits,
such as Naa38p in the NatC (Naa30p/Naa35p/Naa38p) complex and HYPK in the
metazoan NatA/HYPK complex. Currently, our only understanding of auxiliary subunitcontribution to N-terminal acetyltransferase activity and substrate specificity primarily
arises from studies conducted using the heterodimeric S. pombe NatA complex and the C.
albicans NatB complex (Liszczak et al. 2013, Hong et al. 2017). Moreover, we have only
just begun to understand how dysregulation of NAT activity may contribute to human
disease.
In order to develop a model of regulatory subunit contribution to NAT activity and
the involvement of aberrant NAT activity in human disease, the primary focus of my
dissertation research has been on the study of the human NatA complex as a model for
metazoan NatA activity and the NatC complex. In relation to this, I set out to characterize
the biochemical, enzymatic, and structural differences between the previously described S.
pombe NatA complex and the metazoan NatA complex, which has been reported to interact
with the Huntingtin (Htt)-interacting protein, HYPK (Arnesen et al. 2010). In addition, I
set out to utilize the information gleamed about the human NatA and NatA/HYPK
complexes to develop an understanding of their contribution to human disease. To this
end, I determined the structure of the human NatA and NatA/HYPK complexes and carried
out associated biochemical and enzymatic studies. I then performed biochemical and
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enzymatic studies to develop a model for NatA complex missense mutations in Naa10-type
developmental disorders and evaluated the involvement of NatA-mediated Htt N-terminal
acetylation and/or HYPK-interaction in the neurodegenerative Huntington’s Disease (HD).
Finally, I performed biochemical and enzymatic assays to confirm contributions of the
Naa38p auxiliary subunit and/or inositol hexaphosphate (IP6) molecule to NatC complex
activity and thermostability.
Through these studies, I was able to:
(1) Identify distinguishing features of the human NatA complex that contribute
to its activity
(2) Delineate the mechanistic basis for HYPK-mediated NatA regulation
(3) Identify the biochemical and enzymatic effects of clinically-relevant NatA
complex missense mutants in Naa10-type developmental disorders
(4) Evaluate the involvement of either HYPK-binding and/or NatA-mediated
N-terminal acetylation in HD-associated Htt protein aggregation
(5) Determine the roles of Naa38p and IP6 in NatC complex activity
In summary, this work establishes the basis for some of the regulatory mechanisms
involved in NAT activity, and demonstrates the significance of NAT activity regulation in
human health and disease.
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CHAPTER 2
Function and Structure of the Human NatA

Repeated with permission from Gottlieb, L. and Marmorstein, R. (2018). Structure of Human NatA
and Its Regulation by the Huntingtin Interacting Protein HYPK. Structure, 26(7), 925-935 e8. DOI:
10.1016/j.str.2018.04.003 Copyright 2018 Elsevier Ltd.
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2.1 Introduction and Summary of Conclusions
The NatA complex modifies the majority of the human N-terminal acetylome
(Aksnes et al. 2016, Ree et al. 2018). Although the NATs are a conserved class of enzymes,
the metazoan NatA may have functionally distinct features from its yeast counterpart. An
early study by Arnesen and colleagues describing the S. cerevisiae NatA complex found
that expression of the human NatA complex in yeast can form a functional complex,
modify yeast NatA substrates, and rescue a yeast NatA knockdown phenotype, while
heterologous expression of the subunits yields a non-functional complex (Arnesen et al.
2009). Moreover, the human NatA complex can also associate with the Huntingtininteracting protein, HYPK (Huntingtin (Htt) Yeast two-hybrid Protein K), which does not
have a yeast counterpart (Arnesen et al. 2010, Raychaudhuri et al. 2014). Together, this
suggests that the metazoan NatA complex has distinguishing structural features that may
impact its function in metazoans.
In order to assess the evolutionary differences between the previously described S.
pombe NatA (Liszczak et al. 2013) and the metazoan NatA complex, including its
interaction with HYPK, we have determined the structures of the human NatA complex
(described in this chapter) and the NatA/HYPK complex (described in Chapter 3). These
studies reveal unique features of metazoan NatA including a structural inositol
hexaphosphate (IP6) molecule that stabilizes the Naa10-Naa15 interaction and a metazoanspecific Naa15 domain, which contributes to the activity and stability of the NatA
heterodimeric complex. Details elucidated in this study were used to characterize the
interaction between HYPK and the NatA complex.
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2.2 Results
2.2.1 Overall Crystal Structure of the Human NatA Complex
In order to biochemically and structurally characterize the human NatA complex,
we overexpressed the recombinant heterodimeric complex using baculovirus-infected Sf9
cells since previous attempts to co-express the human NatA complex in bacteria cells were
unsuccessful. We found that co-expression of the C-terminally truncated Naa10 subunit
(1-160 out of 235 residues) and full-length N-terminally 6xHis-tagged Naa15 (residues 1866) allowed for the production of soluble, active protein that could be purified to
homogeneity and crystallized. We were able to obtain crystals that formed in the P212121
space group, which contained two heterodimers in the asymmetric unit. Although, we used
sedimentation equilibrium studies to demonstrate that one heterodimer exists in solution
(Figure 11). The 2.80 Å resolution structure was determined using molecular replacement
with the S. pombe (Sp) NatA complex (PDB: 4KVO (Liszczak et al. 2013)) as the initial
search model, and refined to final Rwork and Rfree values of 18.8% and 24.2%, respectively,
with good geometry (Figure 12A and B, Table 1).

Figure 11. Sedimentation Equilibrium of human NatA
(A) Log plot of sedimentation equilibrium experiments a sedimentation experiment showing
theoretical monomer (blue) and theoretical dimer (red) slopes of hNatA (ODA280=0.8) at 12,000 rpm
(black). (B) The corresponding residuals for all three speeds associated with A.
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Figure 12. Overall Structure of hNatA
(A) hNaa10 (light blue) and hNaa15 (dark blue) shown in cartoon over-layed with S. pombe (Sp)
NatA (dark gray) (PDB: 4KVO). Electron density for α33 and α34 helices, annotated with an asterisk
(*), was not resolved in the human structure.
(B) A 90° view rotation of (A) with bound inositol hexaphosphate (IP6) in stick format and annotated
by a dashed box.
(C) Zoom-in view depicting key residues involved in interactions with IP6.
(D) Zoom-in view of the hydrophobic pocket formed at the interface of the hNaa15 α-α23 helices
and C-terminal α44-α45 helices.
(E) Sedimentation velocity of hNatA mutants of Y834, yellow in (D). WT, wild-type.
(F) Differential scanning calorimetric analysis of hNatA mutants.
(G) Bar graph showing the initial velocities of mutants (***pY834F = 0.0001 and ***pY834A < 0.0001
by Student’s unpaired, two-tailed t test). Assays performed in triplicate; error bars SEM.

Table 1. hNatA Complex Data Collection and Refinement Statistics
PDB

6C9M
b

Resolution range (Å)

48.43 - 2.8 (2.9 - 2.8)

b

Space group

P21 21 21

Unit cell dimensions
a, b, c (Å)b

95.11, 171.83, 178.69

b

α, β, γ (°)

90, 90, 90

Total reflectionsc

807,478
b

Unique reflections

72666

c

Multiplicity

Completeness (%)
Mean I/σ (I)

11.1 (11.3)
b

99.94 (99.96)

c

20.8 (1.60)

Wilson B-factorb

82.42
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Table 1. hNatA Complex Data Collection and Refinement Statistics
R-mergeb

0.009 (0.229)

b

R-work

0.1880 (0.2938)

R-freeb

0.2424 (0.3605)

b

0.009

b

1.05

RMS (Å)
RMS (°)
Ramachandran favored (%)b

96.92

b

Ramachandran allowed (%)

2.92

b

Ramachandran outlier (%)

0.16

Rotamer outliers (%)b

0.06

b

Clashscore

Average B-factor

11.08
b

91.41

a numbers

provided in parenthesis correspond to the highest resolution shell.
numbers generated in Phenix.
c numbers retrieved from XDS log file.
b

While the human structure displays a high degree of structural conservation to the
SpNatA structure (1.433 Å R.M.S. deviation over 608 common Cα atoms), there are several
noteworthy features. The hNaa15 auxiliary subunit is composed of 45 α-helices forming a
total of 13 tetracopeptide repeat (TPR) motifs and an additional C-terminal Sel1-like repeat
(SLR) (Karpenahalli et al. 2007, Zimmermann et al. 2018). TPR and SLR segments often
promote protein-protein interactions (Blatch and Lassle 1999, Mittl and SchneiderBrachert 2007), which is consistent with previous studies that have demonstrated that the
Naa15 TPR motifs mediate interactions with Naa50 and HYPK (Neubauer 2012, Weyer et
al. 2017). Using the helical numbering of the S. pombe structure, we did not observe
electron density corresponding to the hNatA α33 and α34 helices, which are presumably
disordered, and the loop-α40-loop segment of the hNaa15 C-terminus is only resolved in
one of the protomer subunits due to stabilization by crystal packing. We also found that
the hNaa10 catalytic subunit was N-terminally acetylated and features an additional Cterminal α-helix (α5) relative to SpNatA (Figure 12A and B).
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Unexpectedly, we observed electron density for inositol hexaphosphate (IP6)
between hNaa10 and hNaa15 bound by a series of electropositive and hydrophilic
interactions within the hNaa10 β2-loop-β3 and β4-loop-α3 segments as well as the hNaa15
α19, α24, and α25 helices (Figure 12C and Figure 13). The hNatA complex primarily
forms hydrogen bonds via positively charged residues to make direct (Naa15: K416, K419,
H420, K447, K450; and Naa10: K78) and water-mediated hydrogen bonds (Naa15: R330),
as well as electrostatic interactions (Naa15: K454 and Naa10: K78) to engage with IP6.
Nearly all of the hNatA residues that make IP6 interactions are well conserved in metazoan
Naa15 and Naa10 (Figure 14 and Figure 15), supporting its biological relevance.

Figure 13. IP6 Fo-Fc Map
Human NatA-bound IP6density contoured to 3.5σ (shown in green).
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Figure 14. Alignment of Naa15 Homologues
Sequence alignment of Naa15 homologues from H. sapiens (Hs); S. pombe (Sp); S. cerevisiae
(Sc); D. rerio subunit b (Dr); G. gallus (Gg); S. scrofa (Ss); P.troglydtes Isoform XI (Pt); M.
musculus (Mm); and R. norvegicus (Rn) demonstrating the divergence of the metazoan Naa15
C-termini (highlighted in yellow) from SpNaa15.
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Figure 15. Alignment of Naa10 Homologues
Sequence alignment of Naa10 homologues from H. sapiens (Hs); S. cerevisiae (Sc); S. pombe
(Sp); A. sinensis (As); and D. rerio subunit b (Dr). The dashed line indicates the truncation
construct used for all experimental studies.

2.2.2 Implications of the Metazoan-Specific Naa15 C-terminal Domain
hNaa15 contains an extended C-terminus (α39-α45) relative to SpNaa15 (Figure
14). This divergent region is comprised of the Sel1-like repeats (residues 798-833), which
extends to wrap back and pack up against the hNaa15 core bottom, forming an additional
ring scaffold. This extended region of hNaa15 appears to play a key role in complex
formation and stability. This is consistent with our observation that deletion of the Cterminus results in the destabilization of the hNatA complex (Figure 16). We also note
that Y834 within a distal loop of hNaa15 interacts with a hydrophobic pocket formed by
P390, S391, I417, Y418 and A421 between the α22-α23 helices and P833, A835, L836
surrounding Y834 within the loop-α45 helix segment (Figure 12D). Notably, these
residues are highly conserved among metazoan Naa15 proteins (Figure 14), but are
charged residues in the α22 of the SpNaa15 auxiliary subunit. To investigate the role of
Y834 in the structural stability and enzymatic activity of hNatA, we mutated Y843 to F
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and A and showed that although the Y843F and Y843A mutants did not significantly
change the shape of the hNatA complex, as measured by sedimentation velocity
experiments (Figure 12E), they did diminish complex stability, as measured by differential
scanning calorimetry, as well as its enzymatic activity (Figure 12F-G). We observed that
wild-type hNatA melted at 46.47 ± 0.011°C, while Y834F and Y834A melted at 45.41 ±
0.0084°C and 41.98 ± 0.012°C, respectively. We also observed a reduction in enzymatic
velocity of the Y834F and Y834A mutants relative to wild-type by 38.6% and 72.7%,
respectively. Consistent with these studies, chimeric expression of either the hNaa10
catalytic subunit or the hNaa15 regulatory subunits with the corresponding S. cerevisiae
NatA subunit yielded a non-functional complex in a S. cerevisiae model system (Arnesen
et al. 2009). Together, these studies demonstrate that the metazoan-specific extended Cterminal segment of hNaa15 makes important contributions to hNatA activity.

Figure 16. C-terminal Truncation of Naa15 Abrogates NatA Binary Complex
Formation
(A) S200 gel filtration chromatogram.
(B) Corresponding SDS-PAGE gel to the trace of HIS-Naa15FL/Naa101-160 complex (red) for
A.
(C) Corresponding SDS-PAGE gel to the trace of HIS-Naa15∆672-866/Naa101-160 complex (blue)
for A.
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2.3 Discussion and Future Studies
While previous studies have detailed the molecular basis for the mechanism of the
SpNatA heterodimeric complex, (Liszczak et al. 2013), we sought to understand the
molecular mechanism its more elaborate metazoan counterpart, which associates with the
intrinsically disordered Huntingtin-associated protein, HYPK.

To do this, we first

determined the X-ray crystal structure of hNatA in the absence of HYPK, described here,
and carried out associated biochemical and enzymatic studies to make structure-function
correlations.
We found two unique features of hNatA relative to SpNatA: an additional ~190
residue C-terminal segment in the hNaa15 regulatory subunit that contributes to hNatA
stability and acetyltransferase function, and a bound IP6 molecule at the hNaa10-hNaa15
interface that also appears to contribute to hNatA stability. While inositol phosphates such
as IP6, more typically play roles in protein signaling cascades and regulating other cellular
processes (Shamsuddin and Bose 2012), there are a handful of other examples of their roles
in mediating protein stability and enzymatic function. This includes the presence of IP6 in
the mammalian adenosine deaminase ADAR1 (Macbeth et al. 2005) and the HopZ1a
acetyltransferase from P. syringae, as well as the presence of IP4 in the histone deacetylase
HDAC3-SMART/DAD complex (Watson et al. 2012).
While these studies have described the significance of the divergence of the
metazoan Naa15 C-terminus, the question remains: what is the function of the divergent
unstructured Naa10 C-terminal domain? Previous studies have demonstrated that the
extended Naa10 C-terminal domain interacts with tuberous sclerosis 2 (TSC2), which has
implications in both development through regulation of retinoic acid production (Naa et al.
2014) and cancer through the inhibition of mTOR (Kuo et al. 2010). Others have reported
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that the extended domain can be phosphorylated (Zhang et al. 2018). Future in vitro studies
should be performed with the full-length Naa10 in the context of the NatA complex.
However, efforts thus far to recombinantly express a full-length heterodimeric hNatA
complex in Sf9 have been unsuccessful. It is possible that recombinant expression of fulllength hNaa10 requires a binding partner, such as hTSC2, or the incorporation of
phosphomimetic residues for stabilization.
Although these studies did not investigate the significance of N-terminal
acetylation of human Naa10, it is possible it may play a role in NatA heterodimeric
complex formation. With an N-terminal sequence of “MNIR-”, the human Naa10 is
expected to be a substrate of the NatB complex (Van Damme et al. 2012). This suggests
an interesting interplay between the NAT enzymes, which may play a role in NAT
regulation, including targeting by the Ac/N-end pathway (Lee et al. 2016). Interestingly,
a number of other NAT subunits in H. sapiens could correspond to potential N-terminal
acetylation substrate sequences (Table 2).
Table 2. Human NATs as NAT Substrates
Substrate Subunit

N-terminal
Sequence

Modifying NAT

Naa10

MNI

NatB

Naa15

MPA

N/A

Naa20

(M)TT

Naa25

(M)AT

Naa30

(M)AE

Naa35

(M)VM

Naa38

(M)AGA

NatD

Naa40

(M)GR

NatE

Naa50

MKG

NatF

NatF

Naa60

(M)TE

NatA

NatH

Naa80

MEL

NatB

Substrate NAT
NatA
NatB

NatC

Parenthesis indicate site of likely methionine excision.
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NatA

Together, these foundational studies lay the groundwork for probing its interaction
with HYPK and the involvement of human NatA in disease while demonstrating the
importance of understanding the development evolutionarily divergent features in the
metazoan NAT enzyme family.
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2.4 Methods
2.4.1 Construction of Baculoviruses
A C-terminal truncation construct coding for the human (h)Naa101-160 and the
(h)Naa15 (866 residues) with an uncleavable N-terminal 6xHis-tag were engineered into a
pFastBac dual vector. Truncations and mutations of the human NatA (hNatA) complex
were generated by introduction of a mutation using Stratagene QuikChange protocol.
Mutant and truncation constructs and the corresponding mutations introduced can be found
in Table 3.
Table 3. Human Naa15 Truncation Constructs
Construct

Mutations

hNaa101-160/hNaa15∆672-866

TAA

hNaa101-160/hNaa15∆Y834F

TTT

Naa101-160/Naa15∆Y834A

GCT

For each of these constructs, a bacmid was generated by transposition into DH10
bac competent E. coli cells using the bac-to-bac system (Invitrogen). Spodoptera
frugiperda (Sf9) cells cultured in SFM II medium were transfected with the bacmid using
cellfectin reagent (Invitrogen). The resulting baculovirus was amplified until reaching a
high titer.
2.4.2 Expression and Purification of 6xHis-tagged Human NatA Constructs
Sf9 cells were grown to a density of 1x106 cells/ml and infected using the amplified
hNaa101-160/hNaa15 (Binary hNatA) baculovirus to an MOI (multiplicity of infection) of
~1-2. The cells were grown at 27°C and harvested 48 hours post-infection. All subsequent
purification steps were carried out at 4°C. Cells were isolated by centrifugation and lysed
in lysis buffer containing 25 mM Tris, pH 8.0, 500 mM NaCl, 10 mM Imidazole, 10 mM
31

β-ME, 10 µg/ml PMSF, DNase, and complete, EDTA-free protease inhibitor tablet
(Roche). The lysate was clarified by centrifugation and incubated with nickel resin
(Thermo Scientific) for 1 hr. before washing the resin with ~125 CV of lysis buffer and
then eluted with 10 CV of elution buffer (25 mM Tris, pH 8.0, 500 mM NaCl, 200 mM
Imidazole, 10 mM β-ME) by batch elution. Eluted protein was diluted to a final salt
concentration of 200 mM NaCl and loaded onto a 5 mL HiTrap SP ion-exchange column
(GE Healthcare). The protein was eluted in the same buffer with a salt gradient (200mM1 M NaCl) over the course of 20 CV. Peak fractions were pooled, concentrated to a volume
of 500 µl (100 kDa concentrator), and loaded onto and run on a Superdex 200 Increase
10/300 GL gel filtration column (GE Healthcare) in sizing buffer containing 25 mM
HEPES, pH 7.0, 200 mM NaCl, and 1 mM TCEP.

Peak fractions were pooled,

concentrated to 4.8 mg/mL, as measured by UV280, and flash-frozen for storage at -80°C
until use. Mutants and human NatA truncations were prepared as described for wild-type
hNatA.
2.4.3 Binary Human NatA Complex Crystallization and Structure Determination
6xHis-tagged binary hNatA (4.5 mg/ml) was incubated with acetyl-CoA (SigmaAldrich) at a 1:3 molar ratio (although acetyl-CoA was not resolved in the final crystal
structure). Crystals were obtained after 6-7 days with hanging-drop vapor diffusion in a
drop containing a 1:1 mixture of protein to a 500 µL well solution containing 16% PEG
3350, 10% tacsimate, pH 7.5. An additive screen (Hampton Research) revealed that
diffraction could be improved when 2% acetone was present as an additive in the drop at a
ratio of 2:1.6:0.4 of protein:well solution:additive. All crystals were cryoprotected by
transferring them to their respective well solutions supplemented with 20% glycerol (EMD
Millipore) before being flash-frozen in liquid nitrogen. Data for the binary hNatA complex
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were collected at beamline 24ID-C at the Advanced Photon Source (Argonne National
Laboratory). All data was processed using XDS (Kabsch 2010).
For phasing, a total of 720 degrees (0.5° per frame) were collected on a single
crystal to reach desirable completeness and redundancy in the P212121 space group, and the
data set was processed to 2.80 Å resolution using 600 frames. SpNatA (4KVO), where the
N-terminus (5-90) and the C-terminus (560-731) in Naa15p were deleted, was used as a
search model in order to generate a solution for the hNatA molecular data set. Refinement
of the binary complex structure was carried out in Phenix using Phenix.refine and, until
final rounds of refinement, two-fold NCS restraints. Manual refinement and additional
model building were performed with Coot. Initially, the N-terminus and C-terminus of
Naa15 were built as polyalanine chains. The final models were checked for errors with a
simulated annealing composite omit map generated by AutoBuild in the Phenix suite.
Statistics for the data set (shown in Error! Reference source not found.) was g
enerated using Phenix, with the exception of Rmerge, redundancy, and mean I/α, which were
retrieved from the XDS log file (Adams et al. 2010, Kabsch 2010).
All distance calculations, as well as three-dimensional alignment R.M.S. deviations
and graphics were generated for publishing in PyMOL (http://www.pymol.org/)
(Schrodinger 2015). All surface area calculations were performed using PDBePISA
(Proteins, Interfaces, Structures and Assemblies) (http://www.ebi.ac.uk/pdbe/pisa/)
(Krissinel and Henrick 2007).
hNaa15

TPR

predictions

were

performed

using

the

TPRpred

(https://toolkit.tuebingen.mpg.de/#/tools/tprpred) (Karpenahalli et al. 2007).
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server

All alignments in the manuscript were performed using Clustal Omega
(https://www.ebi.ac.uk/Tools/msa/clustalo/) (Sievers et al. 2011) and visualized using
ESPript 3.0 (http://espript.ibcp.fr/ESPript/ESPript/) (Robert and Gouet 2014).
2.4.4 Radioactive Acetyltransferase Assays
hNatA acetyltransferase assays were carried out in 100 mM HEPES, pH 8.0, 50
mM NaCl 2 mg/ml BSA, where reactions were incubated with 10 nM of 6xHis-tagged
hNatA (wild-type or mutant) in a 30 µl reaction volume containing 50 μM each of substrate
peptide and [14C]acetyl-CoA (4 mCi/mmol; PerkinElmer Life Sciences) for 12 min at
25°C. The substrate peptide used in the assay corresponds to the first 19 residues of human
H4 (Genscript), which was selected because it did not generate a substrate inhibition kinetic
profile.
To quench the reaction, 20 µl of the reaction mixture was added to negatively
charged P81 phosphocellulose squares (EMD Millipore), and the paper disks were
immediately placed in wash buffer (10 mM HEPES, pH 7.5). The paper disks were washed
three times, at 5 min per wash, to remove unreacted acetyl-CoA. The papers were then
dried with acetone, added to 4 ml of scintillation fluid, and the signal was measured with a
PerkinElmer Life Sciences Tri-Carb 2810 TR liquid scintillation analyzer. Background
control reactions were performed in the absence of enzyme or in the absence of substrate
peptide to ensure that any possible signal due to chemical acetylation was negligible. Each
reaction was performed in triplicate. The counts per minute were converted to molar units
using a standard curve of known [14C]acetyl-CoA concentrations in scintillation fluid.
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2.4.5 Differential Scanning Calorimetry (DSC)
Wild-type and mutant hNatA samples were purified as described above and
prepared in the same sizing buffer by overnight dialysis at 4°C. Samples were recovered
from dialysis and spin filtered to remove particulates (0.22 µm; Millipore). The final
dialysis buffer was also filtered (0.22 µm aPES; Thermo Fisher) and used for all sample
dilutions and as a reference solution for DSC studies. DSC data were collected with a
MicroCal VP-Capillary DSC instrument (Malvern Instruments, Malvern, United
Kingdom).

Prior to sample scans, buffer scans were performed until baseline

reproducibility was achieved. DSC scans of binary hNatA samples were performed at
concentrations of 7-8 µM (WT hNaa15), 8 µM (hNaa15Y834F) and 9 µM (hNaa15Y834A),
respectively. DSC scans were recorded from 10°C to 90°C at a scan rate of 1°C/min with
a pre-scan thermostat of 10 minutes, mid feedback mode and a filtering period of 30
seconds. DSC data were analyzed using Origin 7.0 (OriginLab Corporation, Northampton,
MA). Raw DSC data were corrected for the instrumental baseline by subtraction of a
suitable buffer reference scan. DSC scans of samples were performed in triplicate to ensure
reproducibility. Figure 12F are representative curves from these experiments. Traces
were plotted using MagicPlot Student using the processed data exported from Origin
(https://www.magicplot.com).
2.4.6 Analytical Ultracentrifugation (AUC)
Sedimentation equilibrium AUC experiments were performed at 4°C with
absorbance optics at 280 nm using a Beckman Optima XL-I. We employed the use of a
four-hole rotor containing six-channel centerpieces with quartz windows, spinning at
6,000, 9,000, 12,000 rpm. Samples of 6xHis-tagged hNatA was analyzed at UV280=0.8,
0.5, and 0.2 in sizing buffer. The most representative runs, shown in Figure 11, were
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included to calculate a theoretical molecular weight using the program HeteroAnalysis
(http://www.biotech.uconn.edu/auf/?i=aufftp).
Sedimentation velocity AUC experiments were performed at 20°C with absorbance
optics at 280 nm using the same Beckman Optima XL-I. We employed a rotor containing
two-channel centerpieces with quartz, spinning at 42,000 rpm. Data were obtained over
~8 h of centrifugation. Concentrations of Naa15 variants were achieved by dilution to an
UV280=0.6 in sizing buffer. Data were analyzed using SEDFIT to calculate a continuous
c(s) distribution (Schuck et al. 2002), and data were graphed for visualization using
GraphPad Prism. Representative curves found in Figure 12E.
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CHAPTER 3
The Huntingtin-Interacting Protein HYPK Inhibits Human NatA
Complex Activity

Repeated with permission from Gottlieb, L. and Marmorstein, R. (2018). Structure of Human NatA
and Its Regulation by the Huntingtin Interacting Protein HYPK. Structure, 26(7), 925-935 e8. DOI:
10.1016/j.str.2018.04.003 Copyright 2018 Elsevier Ltd.
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3.1 Introduction and Summary of Conclusions
While NatA contains an evolutionarily conserved eukaryotic auxiliary subunit,
Naa15, higher eukaryotes and some fungi contain a third associated protein called
Huntingtin Yeast two-hybrid Protein K (HYPK) (Arnesen et al. 2010). HYPK was first
identified as a protein that interacts with the Huntingtin protein, which is associated with
the autosomal neurodegenerative Huntington’s disease (Faber et al. 1998). More recently,
HYPK was shown to interact with numerous proteins, including NatA, leading to the
stabilization of HYPK and optimal NatA enzymatic activity towards some substrates
(Arnesen et al. 2010). HYPK is an intrinsically disordered protein that contains homology
to the Nascent Polypeptide-Associated Complex alpha (NACα) within its C-terminal
region, which contains a Ubiquitin Associated (UBA) domain (Raychaudhuri, Majumder,
et al. 2008). Consistent with this homology, HYPK has also been shown to interact with
nascent proteins (Raychaudhuri et al. 2014).
Recent structural and enzymatic studies have shed light on the molecular basis for
NatA substrate specificity and its association with HYPK (Liszczak et al. 2013, Weyer et
al. 2017) . A structure of the S. pombe Naa10/Naa15 complex reveals that binding of the
Naa15 auxiliary subunit induces a conformational change in the Naa10 catalytic subunit,
allowing for enhanced canonical NatA complex substrate binding selectivity (Liszczak et
al. 2013). A more recent structure of Naa10/Naa15/HYPK complex from the thermophilic
fungus Chaetomium thermophilum, reveals that HYPK associates with both the Naa10 and
Naa15 subunits to negatively regulate NatA activity (Weyer et al. 2017).
In this study, we set out to determine the molecular mechanism of regulation of
metazoan NatA by HYPK. To do so, we determined the crystal structure of the human
NatA complex bound by HYPK, characterized and compared the biophysical and
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enzymatic properties of the NatA and NatA/HYPK complexes, and assessed the NatAHYPK interaction by structure-guided mutational analysis studies. These studies reveal
that the unique extended Naa15 C-terminus found in the metazoan NatA facilitates highaffinity HYPK binding. We also show that HYPK has intrinsic inhibitory activity for
human NatA, but not the activity of S. pombe NatA, other NATs or histone
acetyltransferases (HATs); and does so through a bipartite structure that includes the tight
binding of its UBA domain to the metazoan-specific Naa15 region and an N-terminal loophelix region that interacts with Naa10 to distort the active site.

We also provide

biochemical evidence that HYPK binding blocks the targeting of Naa50 to NatA, likely
limiting the localization of Naa50 to the ribosome for co-translational N-terminal
acetylation in vivo. Furthermore, these studies develop a model for the contribution of
NatA missense mutations in heterodimer complex activity and stability. Together, these
studies provide a model for NatA complex regulation by HYPK for protein N-terminal
acetylation and the basis for future work on NatA complex missense mutations, which will
serve as a tool for the study of NAT involvement in developmental disorders.
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3.2 Results
3.2.1 HYPK Exhibits Specific Intrinsic Inhibitory Activity Towards Human NatA
In order to determine the effects of human HYPK on NatA enzymatic activity, we
incubated hNatA with bacterially-produced recombinant human HYPK and measured
hNatA activity against H4 peptide in an in vitro radioactive acetyltransferase assay.
Surprisingly, incubation of human HYPK with the hNatA complex resulted in a significant
reduction in hNatA activity (Figure 17A). To assess the specificity of HYPK to inhibit
other acetyltransferases, we extended our in vitro enzymatic assays to include SpNatA
complex as well as other human NATs (NatB, D, F, and monomeric Naa50) and histone
acetyltransferases (hMOF and hPCAF). We found that HYPK did not inhibit the other
acetyltransferases, although hNatF and hPCAF showed a marginal but significant level of
activation (Figure 17A), likely attributed to the known protein chaperone-like activity of
HYPK (Raychaudhuri, Sinha, et al. 2008, Szolajska and Chroboczek 2011). Previous
studies also showed that HYPK does not interact with NatB or NatC when subjected to
immunoprecipitation (Arnesen et al. 2010), consistent with the enzymatic studies. Also
consistent with the enzymatic results, we used MBP pull-down studies employing MBPHYPK to demonstrate that HYPK directly interacts with hNatA but not SpNatA (Figure
17B), consistent with the hypothesis that HYPK inhibits hNatA through residues that are
divergent with the S. pombe enzyme at the C-terminus of hNaa15 (Figure 14).
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Figure 17. Specific Binding and Inhibition by HYPK to hNatA
(A) Bar graph showing the relative effect of HYPK presence on Nt (NAT) and histone
acetyltransferase (HAT) activity (***phNatA = 0.0003, *phPCAF = 0.0148, and *phNatF = 0.0253, by
Student’s unpaired, two-tailed t test). Reactions were performed in triplicate; error bars SEM.
(B) MBP pull-down assay comparing the ability of HYPK to bind to the human and SpNatA
complexes.

3.2.2 Overall Crystal Structure of the Ternary Human NatA/HYPK Complex
To elucidate the molecular basis for HYPK-mediated hNatA complex inhibition,
we overexpressed the recombinant ternary human NatA/HYPK complex using
baculovirus-co-infected Sf9 cells. We were initially able to obtain crystals of the fulllength HYPK bound to the hNatA complex, but these crystals diffracted poorly. Using a
combination of sequence conservation (Figure 18A), limited proteolysis and LC-MS we
identified an N-terminally truncated HYPK construct (∆1-33), which yielded
hNatA/HYPK crystals that diffracted to 3.15 Å resolution (Figure 18B-D, and Table 4).
The crystals formed in the P63 space group and contained one hNatA/HYPK complex in
the asymmetric unit. We determined the structure of the hNatA/HYPK complex using
hNatA as a molecular replacement model and refined the model to Rwork and Rfree values
of 22.1% and 25.5%, respectively, with good geometry (Table 4).
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Figure 18. Structure of HYPK-Bound hNatA
(A) Sequence alignment of HYPK with nascent polypeptide-associated complex (NAC) proteins
from M. thermautotrophicus (Mt), S. cerevisiae (Sc), H. sapiens (Hs), and S. pombe (Sp). Secondary
structure determined from hNatA/HYPK structure shown with hNaa10 (black square) and hNaa15
contacts (red circle) in the middle. Dashed line indicates construct used for crystallization. Ubiquitinassociated domain (UBA) indicated by black bar.
(B) HYPK-bound hNaa10 (purple) and hNaa15 (dark teal) shown bound to HYPK (light orange) in
cartoon with bound IP6 (stick format).
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(C) HYPK-bound hNatA complex shown in cartoon superimposed with hNaa10 (light cyan) and
hNaa15 (dark blue). hNaa10 α4 is annotated in yellow.
(D) A 90° view rotation of (C).
(E) Zoom-in view of the interface between the HYPK UBA domain (90–129) and the hNaa15 α38
and α40 helices.
(F) Zoom-in view of HYPK-bound hNaa15 in (E) in tube and stick format depicting residues
involved in HYPK-hNaa15 interaction.
(G) A 180° view rotation of (F).
(H) Zoom-in view of the hNaa10 active site demonstrating the obstruction and rearrangement of key
active site residues by HYPK.
(I) Zoom-in view of Y49.
(J) Zoom-in view of E74.

Table 4. hNatA/HYPK Complex Data Collection and Refinement
Statistics
PDB

6C95

Resolution range (Å)b
Space groupb

49.04 - 3.152 (3.265 - 3.152)
P63

Unit cell dimensions
a, b, c (Å)b

182.32, 182.32, 86.07

α, β, γ (°)b

90, 90, 120

Total reflectionsc

119,010

Unique reflectionsb

24588

Multiplicityc

4.84 (4.91)

Completeness (%) b

95.23 (95.94)

Mean I/σc (I)

11.43 (1.2)

Wilson B-factorb

87.76

R-mergeb

0.013 (0.148)

R-workb

0.2207 (0.3762)

R-freeb

0.2552 (0.4348)

RMSb (Å)

0.005

RMSb (°)

0.71

Ramachandran favored (%)b

96.96

Ramachandran allowed (%)b

2.75

Ramachandran outliers (%)b

0.29
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Rotamer outliers (%) b

0

Clashscoreb

9.41

Average B-factorb

95.16

numbers provided in parenthesis correspond to the highest resolution shell.
numbers generated in Phenix.
c numbers retrieved from XDS log file.
a
b

The structure of hNatA/HYPK overlays well with the hNatA structure with an
R.M.S. deviation of 0.617 Å over the common Cα atoms of 776 residues and, like hNatA,
also contains electron density corresponding to IP6. HYPK is composed of five α-helices
that engage with hNatA by forming a clamp around the hNaa15 auxiliary subunit (Figure
18B-D). This clamping causes significant conformational changes to accommodate HYPK
binding (Figure 18C-E), specifically in helices α38/α40 and α1-3 of hNaa15.
The C-terminal α3-5 helices of HYPK adopts a classical UBA (ubiquitinassociated) fold (Hofmann and Bucher 1996, Mueller and Feigon 2002) that facilitates
binding to the hNaa15 C-terminus via the α38/α40 helices and burying a total surface area
of 643.18 Å2 (Figure 18D and E), shifting and stabilizing the hNaa15 α40 helix by ~6 Å.
The contacts made between the HYPK UBA domain and the hNaa15 C-terminus primarily
consist of a network of van der Waals interactions between HYPK (L97, E101, M102,
E103, V121, L124, I125, and T128) and hNaa15 (L689, L690, Q693, T729, T732, V733,
Q736, and E737) as well as a set of hydrogen bonds between the backbone of T100 of
HYPK and K687 of hNaa15, and E101 of HYPK and K685 and a water-mediated
hydrogen-bond with E655 of hNaa15. A network of hydrogen bonds between N129 and
T128 of HYPK with R697 and K696/E737 of hNaa15 caps the hNaa15-UBA domain
interaction (Figure 18A, F, and G). The largely hydrophobic protein interaction properties
of the HYPK C-terminus are typical of proteins featuring a UBA fold, which has been
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shown to facilitate the protein-protein interactions mitigated by other UBA-fold containing
proteins, such as the UV excision protein Rad23A with HIV-1 Vpr (Mueller and Feigon
2002).
The hNaa15 N-terminal α1-3 helices move by ~2-3 Å to accommodate the apex of
the N-terminal HYPK α1 helix (Figure 18A, C, D, and I). There are only a few contacts
with HYPK that facilitates the interaction between both N-termini. hNaa15-H23 shifts by
~3 Å in order to form a π-π interaction with HYPK-Y49 (Figure 18I). hNaa15-R531,
which is already in position for engagement with HYPK in the hNatA structure without
HYPK, makes hydrogen-bond interactions with the backbone carbonyl oxygen atom of
HYPK V46. Additional residues, such as hNaa15 Y528, F525, and D524 shift slightly to
accommodate the HYPK N-terminal helix. In addition, the HYPK N-terminal helix
appears to lay on top of the hNaa10 α2 helix within a hydrophobic pocket, where several
hNaa10 residues including Y30, K29, and Y33 make van der Waals contacts with HYPK
V46 and L43, and hNaa10-Y26 forms a hydrogen bond with HYPK-H35. The N-terminal
loop preceding the HYPK α1 helix, and HYPK-H35 in particular, appears to reorient the
positions of hNaa10-E24, Y26, H110, R112, Y137, and Y138 (Figure 18H).

The

reorientation of residues Y137 and E24, the corresponding residues of which were
previously reported to be involved in SpNatA-mediated catalysis (Liszczak et al. 2013),
likely plays a particularly important role in HYPK-mediated inhibition of hNatA activity.
A 27-residue-long HYPK α2 helix serves to bridge the bipartite interactions
between the α3-5 helices with hNaa15 and the α1 helix with hNaa15 and hNaa10. The
HYPK α2 helix is largely free of hNatA contact except for the N-terminal end, which packs
against the hNaa15 α8-9 helices (Figure 18B and D). HYPK-R71 engages with hNaa15
E135 and Y138 via the formation of a hydrogen bond and a cation-π interaction,
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respectively. HYPK-E74 forms a hydrogen bond with hNaa15-Y158 and an electrostatic
interaction with hNaa15-R134, while the flanking HYPK-R70 forms a salt bridge with
hNaa15-D163 in the α9-loop-α10 segment. The distal HYPK-R81 forms a charged-charged
interaction with hNaa15-E131. A number of van der Waals contacts close the gap between
the HYPK α2 helix (L60, M64, I67, and R70) with hNaa15 (Y138, L141, W151, Y154,
and M166) (Figure 18J). Together, the HYPK α2 helix, as a feature that distinguishes
HYPK from NAC proteins, serves the purpose of directing the HYPK N-terminus into the
hNaa10 active site. The α1-loop-α2 segment threads between the hNaa15 helices, which
hold the loop in place by forming a combination of hydrophobic interactions (HYPK-I55
with hNaa15 F174 and T177), hydrogen bonds and charged-charged interactions (HYPK
K53, E54, and Q56 with hNaa15 R144, R148, and T180).
3.2.3 HYPK Increases NatA Thermal Stability and Deletion and Mutational Analysis is
Consistent with a Bipartite Mode of NatA Inhibition
To quantify the elaborate contacts within hNatA and the impact of HYPK binding
to hNatA, we compared the thermostability of hNatA and hNatA/HYPK using differential
scanning calorimetry. We found that while the hNatA complex melted at 46.47 ± 0.011°C,
the binding of HYPK caused a marked increase of ~6.1°C with a melting temperature of
52.57 ± 0.049°C (Figure 19A).
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Figure 19. Molecular and Thermodynamic Details of HYPK-hNatA Interaction
(A) Differential scanning calorimetric analysis comparing hNatA and hNatA/HYPK complexes.
(B) MBP pull-down assay evaluating the effects of mutations on critical HYPK residues or HYPK
truncation on the hNatA binding. Coomassie-stained SDS-PAGE.
(C) Bar graph evaluating the effect of mutant and truncation HYPK constructs on hNatA
inhibition potency. Assay performed in triplicate; error bars SEM. WT, wild-type.

To probe the functional importance of the crystallographically observed hNatA–
HYPK interactions, we prepared a series of HYPK truncation constructs (∆1-59, ∆60-129,
∆1-33, ∆1-39, ∆1-45, and ∆1-89) and site-directed mutations in the α1 helix (H36A and
L43A/V46A), α2 helix (E74A), and UBA domain (E101A/E103A and V121A/I125A) for
hNatA pull-down and enzymatic studies. The MBP-HYPK pull-down studies revealed that
all the HYPK constructs with the exception of HYPK∆60-129 deletion construct, which lacks
the α2 helix and the UBA domain, were able to pull-down the hNatA complex (Figure
19B). This suggests that most of the binding energy between HYPK and hNatA is mediated
by the α3-α5 UBA domain of HYPK. The observation that none of the double point
mutants in the UBA domain had a discernible effect on HYPK-hNatA complex pull-down,
highlights the strength of this interaction.
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Evaluation of the ability of the HYPK constructs described above to inhibit hNatA
activity, were consistent with the observations made in the crystal structure of the
hNatA/HYPK complex. We observed that substantial relief of inhibition arose from HYPK
mutants H36A, the double L43A/V46A point mutant, the deletion of the loop region before
the N-terminal helix (∆1-39), and the deletion of either the first or second half of HYPK
(∆1-59 or ∆60-129) (Figure 19C). Based on this data, it appears that the primary mode of
inhibition arises from interactions within the hNaa10 active site with the HYPK loop-α1
region (H36 and L43/V46). This is underscored by the release of inhibition upon deletion
of the N-terminal loop or the first half of HYPK, resulting in an increase in hNatA activity
of either ~44% or ~65%, respectively. The observation that HYPK∆1-59 shows drastically
reduced inhibition activity reveals that the HYPK α2 helix and the UBA domain, both
contained within this construct, do not contribute directly to inhibition. However, given
that the UBA domain (residues 90-129) provides most of the binding energy of HYPK to
hNatA, the UBA domain and α2 helix play key roles in HYPK inhibition of hNatA by
bringing HYPK to hNatA and appropriately orienting the loop-α1 region of HYPK into the
hNaa10 active site, respectively.
3.2.4 Mechanism of HYPK-Mediated Human NatA Inhibition
NATs proceed using a bi-bi ordered mechanism where acetyl-CoA binds the NAT
followed by the peptide substrate to form a ternary complex prior to catalysis (Evjenth et
al. 2009, Liszczak et al. 2013). In order to determine the mechanism of HYPK-mediated
inhibition, we characterized the kinetic parameters of the hNatA and hNatA/HYPK
complexes with respect to H4 peptide and acetyl-CoA using an in vitro acetyltransferase
assay (Figure 20A and B, and Table 5).
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Table 5. Catalytic Parameters for Wild-Type hNatA and hNatA/ HYPK Complexes
Complex

kcat (min-1)

KM (µM)

kcat/KM (µM min-1)

hNatA

150 ± 8.9

27 ± 3.9

5.5 ± 0.86

hNatA/HYPK

10 ± 0.39

1.7 ± 0.31

6.1 ± 1.1

hNatA
hNatA/HYPK
Errors represent S.E.M. (n=3)

200 ± 8.1
16 ± 1.6

30 ± 3.6
31 ± 9.5

6.8 ± 0.90
0.52 ± 0.10

Substrate
Acetyl-CoA
H4 peptide

Figure 20. Mechanism of NatA Inhibition
(A–C) Michaelis-Menten kinetics of hNatA and hNatA/HYPK complexes (10 nM) with respect
to (A) H4 and (B) acetyl-CoA.
(C) Dose-response curve corresponding to titration of full-length MBP- HYPK recombinant
protein, HYPK peptide (containing the residues 35–48), and the nonspecific gag peptide.
(D) Overlay of the SASE-CoA bisubstrate inhibitor (PDB: 4KVM, CMK stick format) bound in
the hNatA-HYPK active site.
(E) Morrison inhibition plot of the dose-response curve corresponding solely to the titration of
full-length MBP-HYPK recombinant protein. Assays performed in triplicate; error bars
correspond to the SEM for each point.

We found that HYPK-binding decreased H4 peptide kcat ~12-fold while KM
remained the same. By contrast, HYPK binding resulted in a reduction in kcat by ~15-fold
and KM ~14-fold with respect to acetyl-CoA. It is interesting to note that HYPK improves
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the ability of acetyl-CoA to bind hNatA (lowers KM) such that the concentration is within
a physiological range (~2-13 µM) (Lee et al. 2014), suggesting that HYPK acts to
potentiate hNatA for acetyl-CoA binding and potentially sensitize hNatA towards acetylCoA flux similar to other acetyltransferases (Pietrocola et al. 2015). Based on this
mechanistic data and the incomplete inhibition pattern, we propose that binding of HYPK
to hNatA results in partial uncompetitive inhibition with respect to acetyl-CoA and partial
noncompetitive inhibition with respect to peptide.
The changes in kinetic parameters observed upon binding of HYPK to hNatA are
consistent with the details observed in the structure. The HYPK N-terminal loop displaces
the characteristic NAT β-hairpin (β6-loop-β7) that participates in substrate protein binding
(Liszczak et al. 2011) by ~3-4 Å, likely causing the altered shape of the hNaa10 α4 helix
and, consequently, the acetyl-CoA binding pocket (Figure 18C, Figure 18H, and Figure
20C). Furthermore, we found that hNaa10-R82 and R83, the corresponding residues of
which participate in acetyl-CoA binding in the SpNatA structure, are well-ordered in the
hNatA structure but are disordered and, in turn, potentially more accommodating for
acetyl-CoA binding in the hNatA/HYPK structure. The repositioning of the NAT β-hairpin
likely also contributes to the inability of the active site to promote catalysis. The
restructuring of the peptide binding pocket upon binding of HYPK to hNatA by the
repositioning of the key residues that contribute to catalysis, hNaa10-H110, R112, and
Y138 (as demonstrated by studies using SpNatA (Liszczak et al. 2013)), likely contributes
to a decrease in the kcat. Additionally, HYPK-K34 makes backbone hydrogen bonds with
hNaa10-Y137 and HYPK-H35 forms a hydrogen bond with hNaa10-Y26, fastening the
HYPK N-terminus in place. Consequently, HYPK H35 sterically clashes with the hNatA
general base residue, E24, causing the reorientation of the carboxylic acid moiety.
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Superposition of the human hNatA/HYPK structure with SpNatA bound to a bisubstrate
inhibitor reveals that the N-terminal loop of HYPK sterically clashes with only residue four
of the peptide moiety (Figure 20C), does not engage with any of the peptide binding
residues, and all of the peptide binding residues maintain their same position (Figure 18H).
This observation demonstrates that HYPK binding to hNatA does not perturb
peptide binding and is consistent with the noncompetitive nature of HYPK and peptide
binding to hNatA.
To quantify and parse out the details HYPK-mediated hNatA inhibition, we
conducted inhibition studies using either full-length recombinant MBP-tagged HYPK, a
synthetic HYPK peptide corresponding to the N-terminal loop-α1 helix (residues 35-48),
or a non-specific gag peptide corresponds to the first seven residues of the sequence of the
S. cerevisiae NatC substrate (Figure 20D). We found that we were unable to fit a halfmaximum concentration curve (IC50) for the recombinant HYPK due to the tight-binding
properties of the interaction between HYPK and the hNatA complex. However, we were
able to determine that the HYPK35-48 peptide has a modest IC50 of 420 ± 24 µM, which,
taken together with the pull-down of HYPK truncations and mutants, is consistent with the
mechanism of binding primarily arising from the UBA domain.
Due to the tight-binding affinity between HYPK and hNatA, we performed
enzymatic assays under stoichiometric binding conditions. Using a tight-binding equation
modified to incorporate a partial noncompetitive mode of inhibition (see 3.4 Methods), we
calculated a Ki of 0.7 ± 0.3 nM (Figure 20D). Consistent with the observed tight-binding
capacity of HYPK with hNatA, other studies have found that the hydrophobic patch of the
UBA domain is responsible for as low as low-nanomolar (Wilkinson et al. 2001,
VanderLinden et al. 2017) to micromolar dissociation constants (Hurley et al. 2006).
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3.2.5 HYPK Blocks Human Naa50 Recruitment to the Human NatA Complex in vitro
In order to determine whether hNatA could form a complex concurrently with
HYPK and hNaa50, we superimposed the hNatA and hNatA/HYPK structures with the S.
cerevisiae (Sc) NatA/Naa50 structure (PDB: 4XPD (Neubauer 2012)). Interestingly, we
observed that the hNaa15 helical bundle that contacts HYPK shifts towards HYPK (α38α40), while it shifts away from HYPK (in the opposite direction) in ScNaa15 relative to
the corresponding helical bundle in hNatA alone (Figure 21A). This difference in helical
position appears to result in different hNaa15 surfaces for hNaa50 binding, which is
dependent on HYPK binding to hNatA (Figure 21B), suggesting that HYPK and hNaa50
binding to hNatA may be mutually exclusive. To test this hypothesis, we performed
competition pull-down studies by incubating either MBP-HYPK∆1-33 (crystallization
construct) or GST-hNaa50 with hNatA and competing with either untagged hNaa50 or
untagged HYPK∆1-33, respectively. We found that hNaa50 did not pull-down with MBPHYPK∆1-33 preincubated with hNatA. In contrast, we observed an appreciable decrease in
hNatA pull-down by GST-tagged hNaa50 in the presence of HYPK∆1-33 (Figure 21C),
which suggests that the order of binding influences the composition of hNatA-mediated
complex formation. Taken together, this observation indicates a preferential order of
binding of HYPK to hNatA. This is likely a result of HYPK tight-binding in conjunction
with the incompatibility of the HYPK-induced conformational change with the changes
necessary for simultaneous HYPK/Naa50 binding and Naa50 recruitment to the ribosome
for NatE-mediated co-translational catalysis. This is consistent with previous studies
indicating that the majority of endogenous hNaa50 does not associate with hNatA (Hou et
al. 2007).
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Figure 21. HYPK Binding Reduces hNatA Capacity to Bind Naa50
(A) Overlay of S. cerevisiae (Sc) Naa50-bound NatA (PDB: 4XPD; ScNatA, green;
ScNaa50, magenta) with hNatA (dark blue) and HYPK (light orange) bound to hNatA
(dark teal). Helices are illustrated in cylindrical cartoons and enumeration of hNatA
helices are indicated. Arrows indicate the direction of Naa15 conformational change
induced upon HYPK (dark teal) or Naa50 (green) binding.
(B) A 90° view rotation of (A).
(C) Competition pull-downs of HYPK and hNaa50 binding to hNatA with MBPHYPK∆1-33 as bait in the presence of amylose resin (left) and GST- hNaa50 as bait in the
presence of glutathione resin (right).
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3.3 Discussion and Future Directions
While the molecular basis for the function of SpNatA has previously been described
(Liszczak et al. 2013), we set out to understand the molecular mechanism of regulation of
its more elaborate metazoan counterpart via its association with the intrinsically disordered
protein, HYPK. To do this, we first determined the X-ray crystal structure of hNatA in the
absence of HYPK, described in Chapter 2, as well as in the presence of HYPK (this
Chapter) and carried out associated biochemical and enzymatic studies to make structurefunction correlations.
This study describes the molecular basis for interaction between hNatA complex
with its binding partner, HYPK. Our findings show that HYPK specifically inhibits hNatA
over SpNatA, as well as other NATs and HATs. To our knowledge, this is the first protein
with intrinsic acetyltransferase inhibitory activity. Due to the tight and stabilizing nature
of the hNatA-HYPK interaction with a calculated Ki of 0.7 nM, our findings suggest that
the metazoan NatA and HYPK form an obligate ternary complex in vivo. This is consistent
with earlier studies showing that siRNA-mediated hNatA or HYPK knockdown in HeLa
cells leads to similar phenotypes of cell death and cellular accumulation in the G1/G0 phase
(Arnesen et al. 2010). We find that HYPK uses a bipartite mode of hNatA inhibition in
which a C-terminal UBA three-helix bundle (α3-α5) mediates high affinity binding to the
hNaa15 auxiliary subunit while an N-terminal loop-helix segment (loop-α1) interacts with
hNaa15 and the hNaa10 active site to interfere with catalysis. The partial uncompetitive
and noncompetitive modes of HYPK inhibition with respect to acetyl-CoA cofactor and
N-terminal peptide sequence, respectively, assures that HYPK promotes acetyl-CoA
binding so that hNatA interacts with acetyl-CoA in the physiological range of ~1 µM, and
is also able to be displaced by peptide substrate that emerges from the ribosome exit tunnel.
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While HYPK inhibits the intrinsic activity of NatA in vitro, it likely plays a more nuanced
regulatory role in vivo. Taken together, we hypothesize that HYPK may serve as a hNatA
substrate proofreading mechanism for hNatA activity.
Unexpectedly, a superposition of the human hNatA/HYPK structure reported here
with a ScNatA/ScNaa50 structure, reveals that although HYPK and Naa50 bind to different
NatA surfaces, they mediate NatA conformational changes that are incompatible with
simultaneous binding of HYPK and Naa50 to NatA, which we confirm using competition
pull-down studies.

These findings suggest that HYPK may indirectly inhibit co-

translational NatE (NatA/Naa50) activity in cells since Naa50 is targeted for cotranslational N-terminal acetylation through its interaction with NatA at the ribosome. In
contrast to these findings, a previous study in D. melanogaster reported that Naa50 coimmunoprecipitates with HYPK and the NatA complex (Rathore et al. 2016). In light of
this finding, it is possible that an additional cellular protein could facilitate the
simultaneous binding of HYPK and Naa50 to NatA. An additional superposition of the
hNatA/HYPK complex with NatA/HYPK structure from the thermophilic fungus
Chaetomium thermophilum, reveals a similar mode of bipartite HYPK binding to NatA,
further reinforcing a degree of evolutionary conservation in the mode of intrinsic HYPK
inhibition of NatA (Weyer et al. 2017) and potentially also Naa50 binding.
Although we demonstrate that HYPK uses a bipartite mechanism for robust hNatA
inhibition (Ki of 0.7 nM), we are able to show that a peptide harboring the N-terminal loophelix (residues 35-48) segment of HYPK is able to inhibit hNatA with a modest but
significant IC50 of ~400 µM. This result clearly highlights the importance of the UBA
domain in HYPK inhibition of NatA, but also points to the possibility of elaborating on the
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N-terminal loop-helix HYPK segment for the development of small molecule hNatA
inhibitors.
HYPK contains a Nascent polypeptide-Associated Complex alpha (NACα) domain
(residues 90-129, α3-α5 (Raychaudhuri et al. 2014)). The NAC complex interacts with the
ribosome, potentially interacts with the chaperone Hsp70, and contacts nascent peptides
(Andersen et al. 2007, Koplin et al. 2010). Unlike the NAC proteins, however, HYPK
contains additional α-helices (α1-α2) while NAC proteins contains N-terminal β-sheets,
which are responsible for NAC complex dimerization (Liu et al. 2010). These architectural
differences indicate that NatA would not likely form a complex with a NAC protein;
however, future studies should interrogate the possibility of this interaction. Since our
study suggests that HYPK is likely constitutively associate with NatA, which is known to
associate with the ribosome and nascent polypeptides, we propose that HYPK also interacts
with these molecules as well, possibly to facilitate N-terminal acetylation fidelity. HYPK
has also been reported to interact with Huntingtin protein and to reduce Huntingtin
aggregation (Raychaudhuri, Sinha, et al. 2008, Arnesen et al. 2010). Interestingly, the Nterminal sequence of ATLEK- found in Huntingtin protein, would be predicted to be a
substrate for NatA and, by consequence, a possible target for the N-end pathway
(Varshavsky 2011). Whether these observations are just coincidence or functionally
connected will require further investigation. Taken together, these studies redefine the
composition of the hNatA complex in metazoan species and describe the unique intrinsic
NAT inhibitory properties of HYPK, providing a model for HYPK regulation of NatAmediated protein N-terminal acetylation.
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3.4 Methods
3.4.1 Construction of E. coli Expression Vectors
A pET-m41 vector engineered to contain an N-terminally MBP-tagged human
HYPK was kindly donated to us by Thomas Arnesen (University of Bergen). MBP-HYPK
was N-terminally truncated (∆1-59, ∆1-33, ∆1-39, ∆1-45, and ∆1-89) and mutated (H36A,
E74A, L43A/L46A, E101A/E103A, and V121A/I125A) using ‘round the horn’ site
directed mutagenesis with the pET-M41 HYPK vector as a template (IDT). MBPHYPK∆60-129 was constructed through the introduction of a TGA mutation into HYPK by
the Stratagene QuikChange protocol. Mutant HYPK constructs and their corresponding
mutations can be found in Table 6.
Table 6. Mutant HYPK Constructs
HYPK Construct

Mutation

HYPKE36A

GCG

HYPKE74A

GCC

HYPKL43A/L46A

GCG/GCC

HYPKE101A/E103A

GCG/GCG

HYPKV121A/I125A

GCG/GCA

3.4.2 Construction of Baculoviruses
Studies were performed with a hNaa15 subunit that contained either an uncleavable
N-terminal 6xHis-tag or a TEV-cleavable 6xHis-tag, as indicated below.
MBP-tagged full-length human HYPK was subcloned from the pET-m41
expression vector into a pFastBac 1 vector. MBP-HYPK∆1-33 was generated using ‘round
the horn’ site directed mutagenesis with the pFastBac 1 MBP-HYPK vector as a template.
A full-length tobacco etch virus (TEV)-cleavable 6xHis-tagged human NatB (hNatB)
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construct, consisting of Naa20 (178 residues) and Naa25 (972 residues), was also
engineered using a pFastBac dual vector.
For each of these constructs, a bacmid was generated by transposition into DH10
bac competent E. coli cells using the bac-to-bac system (Invitrogen). Spodoptera
frugiperda (Sf9) cells cultured in SFM II medium were transfected with the bacmid using
cellfectin reagent (Invitrogen). The resulting baculovirus was amplified until reaching a
high titer.
3.4.3 Expression and Purification of 6xHis-tagged Human NatA Constructs
Sf9 cells were grown to a density of 1x106 cells/ml and infected using the amplified
Naa101-160/Naa15 baculovirus to an MOI (multiplicity of infection) of ~1-2. The cells were
grown at 27°C and harvested 48 hours post-infection. All subsequent purification steps
were carried out at 4°C and as described for the WT hNatA in Section 2.4.2.
3.4.4 Expression and Purification of MBP-tagged HYPK Constructs
All MBP-tagged HYPK constructs were expressed in Rosetta (DE3)pLysS
(Millipore) competent E. coli cells. Cells were grown in LB media (Millipore) at 37°C to
OD600 0.6-0.7 prior to inducing protein expression with 0.5 mM isopropyl β-D-1thiogalactopyranoside (IPTG) at 18°C for ~16 hrs. All subsequent purification steps were
carried out at 4°C. Cells were isolated by centrifugation and lysed in lysis buffer containing
25 mM Tris, pH 8.0, 150 mM NaCl, 10 mM β-mercaptoethanol (β-ME), 10 µg/ml
phenylmethanesulfonylfluoride (PMSF), and DNase (Invitrogen). The lysate was clarified
by centrifugation and incubated with amylose agarose resin (New England Biolabs) for 1
hr. before washing the resin with ≥80 column volumes (CV) of lysis buffer and then eluted
with 10 CV of lysis buffer supplemented with 20 mM maltose by batch elution. Eluted
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full-length and truncated MBP-HYPK constructs were loaded onto a 5-mL HiTrap Q ionexchange column (GE Healthcare). The protein was eluted in the same buffer with a salt
gradient (150 mM – 1 M NaCl) over the course of 20 CV. Peak fractions were pooled and
concentrated to a volume of 500 µl (50 kDa concentrator; Amicon Ultra, Millipore), and
loaded onto and run on a Superdex 200 Increase 10/300 GL gel filtration column (GE
Healthcare) in gel filtration buffer containing 25 mM HEPES, pH 7.0, 200 mM NaCl, and
1 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP). Peak fractions were pooled
and concentrated to ~20-40 mg/mL by UV280 (Nanodrop 2000; Thermo Fisher Scientific),
and flash-frozen for storage at -80°C until use. Later studies were performed using samples
prepared from peak fractions that had been pooled after ion exchange, dialyzed into gel
filtration buffer and flash-frozen.

Initially, pull-down and inhibition studies were

performed using samples purified by gel filtration chromatography, however, results
between gel filtration-purified and ion exchange-purified samples were identical. HYPK
mutants and truncation constructs were purified following the same protocols with the
following changes. Subsequent to elution from the amylose affinity column, the eluent
was immediately purified by gel filtration chromatography to confirm proper folding.
3.4.5 Expression and Purification of Human NatA/HYPK
Sf9 cells were grown to a density of 1x106 cells/ml and co-transfected with an equal
volume of the MBP-HYPK and TEV-cleavable 6xHis-tagged hNatA baculoviruses to an
MOI of ~1-2. The cells were grown at 27°C and harvested 48 hours post-infection. All
purification steps were carried out at 4°C and are identical to the protocol implemented for
the WT heterodimeric hNatA complex described in Section 2.4.2, with the following
changes for the production of ternary complex for X-ray diffraction studies. After elution
from the nickel column, the eluted protein was diluted to a final NaCl concentration of
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~267 mM and incubated overnight with TEV protease to cleave the MBP- and 6xHis-tags.
The MBP-cut protein was then diluted to the final NaCl concentration of 200 mM and
loaded onto the SP ion-exchange column.
3.4.6 Human NatA/HYPK Crystallization and Structure Determination
Ternary hNatA/HYPK (4.2 mg/ml) was incubated with acetyl-CoA at a 1:3 molar
ratio (although density for acetyl-CoA was not resolved in the crystal structure). Initial
crystals were obtained after 1-2 days with hanging-drop vapor diffusion in a drop
containing a 1:1 mixture of protein to a 500 µL well solution containing 21% PEG 3350,
10% tacsimate, pH 6.5 at 20°C, and yielded poor diffraction. These crystals were used as
seeds (1:100,000) for further optimization where large crystals were obtained in a 1:1:0.2
mixture of protein, well solution (19.5% PEG 3350, 11% tacsimate, pH 6.5), and seed
solution. All crystals were cryoprotected by transferring them to their respective well
solutions supplemented with 20% glycerol before being flash-frozen in liquid nitrogen.
Data for the hNatA/HYPK complex were collected at beamline 24ID-C at the Advanced
Photon Source.
For phasing, a total of 360 degrees (1° per frame) were collected on a single crystal
to reach desirable completeness and redundancy in the P63 space group, and the data set
was processed to 3.15 Å resolution HYPK using 80 frames. The hNatA structure was used
as a search model in order to generate a solution for the ternary hNatA/HYPK molecular
data set and HYPK was initially built as a polyalanine chain. All data processing and
refinement was performed using the same software packages detailed previously in Section
2.4.3.
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3.4.7 Expression and Purification of Other NAT and HAT Enzymes
hNatB was produced from Sf9 cells, as described in Section 2.4.2. All subsequent
purification steps were carried out at 4°C. Cells were isolated by centrifugation and lysed
in lysis buffer containing 25 mM Tris, pH 8.0, 300 mM NaCl, 10 mM Imidazole, 10 mM
β-ME, 10 µg/ml PMSF, DNase, and complete, EDTA-free protease inhibitor tablet. The
lysate was clarified by centrifugation and incubated with nickel resin for 1 hr. before
washing the resin with ~125 CV of lysis buffer supplemented with a final concentration of
25 mM Imidazole and then eluted with 2 CV of elution buffer five times (25 mM Tris, pH
8.0, 300 mM NaCl, 200 mM Imidazole, 10 mM β-ME) by batch elution. The resulting
eluent was pooled, cut overnight with TEV protease to remove the 6xHis-tag, and dialyzed
into 25 mM Tris pH8 300 mM NaCl 5 mM Imidazole 10 mM β-ME. The protein was then
incubated on nickel column for an hour, after which the flow-through was collected and
dialyzed overnight into 25 mM HEPES pH 7.5 50 mM NaCl 10 mM β-ME. The protein
was loaded onto an SP ion exchange column and eluted in the same buffer with a salt
gradient (50-750 mM NaCl) over the course of 20 CV. Peak fractions were pooled,
concentrated to a volume of 500 µl (100-kDa concentrator), and loaded onto and run on a
Superdex 200 Increase 10/300 GL gel filtration column in the same sizing buffer as hNatA.
Peak fractions were pooled, concentrated to ~6 mg/mL, as measured by UV280, and flashfrozen for storage at -80°C until use.
Full-length human NatD (hNatD; 237 residues) was engineered into a pCDF vector
containing an N-terminal TEV-cleavable 6xHis-tag. hNatD was expressed using Rosetta
(DE3)pLysS (Millipore) competent E. coli cells, which were grown in LB media
(Millipore) at 37°C to an OD600 of ~0.7-0.9 and induced by addition of 0.5 mM IPTG at
16°C for 16 hr. All subsequent purification steps were carried out at 4°C. Cells were
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isolated by centrifugation, lysed by sonication in lysis buffer containing 25 mM Tris, pH
8.0, 1 M NaCl, 10 mM β-ME and 10 mg/mL PMSF. The lysate was clarified by
centrifugation and passed over nickel resin, which was subsequently washed with >20 CV
of lysis buffer supplemented with 25 mM imidazole. The protein was eluted in lysis buffer
supplemented with 300 mM imidazole by batch elution. The 6xHis-tag was cleaved
overnight by addition of 6xHis-tagged TEV-protease during dialysis into dialysis buffer
containing 25 mM Tris, pH 8.5, 200 mM NaCl, 10 mM β-ME This solution was passed
through an additional nickel column to remove TEV protease as well as any uncut hNatD.
The resin was then washed with approximately 7 CV of dialysis buffer supplemented with
25 mM imidazole, which was pooled with the initial flowthrough. This solution was
dialyzed into ion exchange buffer containing 25 mM Tris, pH 8.5, 50 mM NaCl and 1 mM
dithiothreitol (DTT) and loaded onto a 5 ml HiTrap Q ion exchange column. The protein
was eluted in the same buffer with a salt gradient (50–750 mM NaCl) over the course of
20 CV. Peak fractions were pooled and dialyzed into sizing buffer containing 25 mM
HEPES, pH 7.0, 200 mM NaCl, and 1 mM DTT for ~16 hours. This was concentrated to a
volume of 500 ml (10-kDa concentrator), and loaded onto and run on a Superdex 75prep
gel filtration column (GE Healthcare) in sizing buffer. Peak fractions were concentrated
to 10 mg/ml as measured by UV280 and flash-frozen for storage at -80°C until use (Magin
et al. 2015).
The full-length human Naa50 (hNaa50) pETM-GST vector was engineered into a
pETM-GST vector with an N-terminal TEV-cleavable GST tag. hNaa50 was expressed
using BL21(DE3) cells (Millipore), which were grown at 37°C to an OD600 of ~0.7 and
induced by addition of 0.5 mM IPTG at 18°C for 16 hr. All subsequent purification steps
were carried out at 4°C. Cells were isolated by centrifugation and lysed by sonication in
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lysis buffer containing 25 mM HEPES pH 7.5, 100 mM NaCl, and 10 mM β-ME. The
supernatant was isolated and passed over GST-binding resin (Gold Biotechnology).
Unbound proteins were washed off the resin with lysis buffer, and TEV was added directly
to the resin and allowed to incubate overnight at room temperature. Untagged hNaa50 was
washed off the resin with lysis buffer, collected, dialyzed into low-salt buffer (25 mM
HEPES pH 7.5, 50 mM NaCl, and 10 mM β-ME) and bound to a 5-ml HiTrap SP ion
exchange column. The protein was eluted in the same buffer using a salt gradient of 50–
750 mM NaCl and further purified to homogeneity using a S75 gel filtration column in
storage buffer (25 mM HEPES pH 7.5, 100 mM NaCl, and 10 mM DTT). Peak fractions
were concentrated to ~12 mg/ml using a 10-kDa protein concentrator and then stored at 80°C until use (Liszczak et al. 2011). GST-tagged protein was produced following the same
protocol with the following exceptions. Glutathione-resin bound hNaa50 was eluted from
the resin using lysis buffer supplemented with 20 mM glutathione. The eluent was then
dialyzed for ion exchange overnight.
A C-terminal truncation construct coding for 6xHis-SUMO-hNaa60 (5-184)
(hNatF) was expressed in Rosetta (DE3) pLys (Millipore) E. coli competent cells overnight
at 17°C using 0.5 mM IPTG. Cells were lysed by sonication in lysis buffer (25 mM TrisHCl pH 8.0, 1 M NaCl, 10 mM β-ME, and 10 mg/ml PMSF), the cell lysate was clarified
by centrifugation, and overexpressed His-tagged protein was isolated by passing the
supernatant over nickel resin. Subsequent purification steps were performed at 4°C. The
resin was washed with wash buffer (25 mM Tris-HCl pH 8.0, 250 mM NaCl, 20 mM
imidazole, 10 mM β-ME) and bound proteins eluted by slowly increasing the imidazole
concentration to 300 mM. The 6xHis-SUMO tag was cleaved by adding SUMO protease
(Ulp-1) to the eluted protein while the protein was dialyzed into a buffer without imidazole
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(25 mM Tris-HCl pH 8.0, 250 mM NaCl, and 10 mM β-ME), and the tag was removed
from the sample by reverse nickel purification. The flowthrough was collected and dialyzed
into size-exclusion buffer (25 mM HEPES pH 7.5, 300 mM NaCl, and 1 mM DTT). The
dialyzed sample was concentrated to a final volume of 1 ml and loaded on a HiLoad
Superdex 200 size exclusion chromatography column. Fractions containing hNaa605–184
were collected and concentrated to ~20 mg/mL and flash-frozen for storage at -80°C until
use (Stove et al. 2016).
The full-length S. pombe Naa15 (729 residues) was engineered into MCSI of a pET
DUET vector containing a TEV protease-cleavable 6XHis-tag with MCSII containing
Naa10 (1-156). The S. pombe NatA (SpNatA) construct was transformed into Rosetta
(DE3)pLysS competent (Millipore) E. coli cells, grown to an OD600=0.7 and induced with
0.5 mM IPTG at 16°C for ~16 hours. Cells were isolated by centrifugation and lysed by
sonication in a buffer containing 25 mM Tris pH 8.0, 500 mM NaCl, 10 mM β-ME and
PMSF. Subsequent purification steps were performed at 4°C. The solution was isolated
and passed over nickel resin, which was subsequently washed with >20 CV of lysis buffer
supplemented with 25 mM imidazole. The protein was eluted using batch elution with
buffer containing 200 mM imidazole and TEV protease was added to fractions containing
the target protein for the duration of a 14-hour dialysis into lysis buffer. The solution was
passed through an additional nickel column to remove TEV protease and 6xHis-tagged
spNatA. The resin was then washed with ~ 7 CV of lysis buffer supplemented with 25 mM
imidazole, which was pooled with the initial flowthrough. This solution was dialyzed into
a buffer containing 25 mM sodium citrate monobasic pH 5.5, 100 mM NaCl and 2 mM
DTT and loaded onto a 5 mL HiTrap SP ion exchange column. The first of two peaks was
concentrated to 1 mL, and loaded onto an s200prep gel filtration column (GE Healthcare)
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in a buffer containing 25 mM HEPES pH 7.0, 200 mM NaCl and 1 mM TCEP. This protein
was concentrated to 15 mg/mL as measured by UV280 until use (Liszczak et al. 2013).
The HAT domain of human MOF (hMOF; residues 174-449) was engineered into
a pRSF vector with an N-terminal 6xHis-tag separated by a TEV protease recognition. The
hMOF plasmid was transformed into E, coli BL21(DE3) codon plus RIL (Stratagene) cells
and the protein was overexpressed in terrific broth media (DOT Scientific), induced with
1mM IPTG at OD600 ~0.8–1.5, and grown at 15°C overnight. The cells were harvested and
lysed by sonication in lysis buffer (50 mM HEPES pH 7.5, 0.5 M NaCl, 2 mM β-ME, 5
mM imidazole, 5% glycerol, 0.1% CHAPS, and PMSF), and the lysate was clarified by
centrifugation.

Subsequent purification steps were performed at 4°C. The lysate

supernatant was loaded onto nickel resin equilibrated with lysis buffer. The resin was
washed with 10 CV of lysis buffer containing 25 mM imidazole. The protein was eluted
with lysis buffer containing 250 mM imidazole buffer in 10-ml fractions. The eluent was
concentrated and injected onto an FPLC using a HiLoad Superdex 75 16/60 gel filtration
column using sizing buffer (20mM HEPES pH 7.5, 0.5 M NaCl). Peak fractions were
concentrated to ~5-15 mg/mL (10-kDa protein concentrator) as measured by UV280 and
flash-frozen for storage at -80°C until use (McCullough et al. 2016).
The HAT-domain of human PCAF (hPCAF; residues 443-657) was engineered into
a pET-28 and expressed in Rosetta(DE3) pLys (Millipore) competent cells overnight at
18°C using 0.5 mM IPTG. Cells were lysed by sonication in lysis buffer containing
phosphate buffer pH 7.4 (Thermo Fisher) containing 10 mM β-ME, and 10 mg/ml PMSF,
the cell lysate was clarified by centrifugation, and overexpressed His-tagged protein was
isolated by passing the supernatant over nickel resin. The resin was washed with lysis
buffer supplemented with 25 mM imidazole and bound proteins eluted by batch elution
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using lysis buffer supplemented with 200 mM imidazole. The eluent was dialyzed into lowsalt buffer (20 mM Sodium Citrate pH 6.0, 20 mM NaCl, and 10 mM β-ME) and bound to
a 5-ml HiTrap SP ion exchange column. The protein was eluted in the same buffer using a
salt gradient of 20–1 M NaCl and further purified to homogeneity using a S75 gel filtration
column in storage buffer (20 mM Sodium Citrate pH 6.0, 150 mM NaCl, and 1 mM TCEP).
Peak fractions were concentrated to ~2 mg/ml using a 10-kDa protein concentrator and
stored at -80°C until use.
3.4.8 hNatA Radioactive Acetyltransferase Assays
hNatA acetyltransferase assays were carried out as described previously in Section
2.4.4, where reactions were incubated with 10 nM of 6xHis-tagged hNatA alone or mixed
with 5 μM MBP-HYPK (wild-type or mutant) in a 30 µl reaction volume containing 50
μM substrate peptide and [14C]acetyl-CoA. We did observe comparable HYPK-mediated
inhibition of hNatA towards the H4 substrate peptide corresponding to the in vivo substrate,
SASEA.
In order to determine steady-state catalytic parameters of hNatA, a saturating
concentration of radiolabeled [14C]acetyl-CoA (100 µM) was incubated at seven different
concentrations of the substrate peptide (ranging from 3.9–250 µM). Additionally,
the acetyl-CoA Km values were determined by titration of the acetyl-CoA at eight different
concentrations (ranging from 0.73 to 94 μM) in the presence of 350 µM substrate peptide.
Assays were performed in the presence and absence of MBP-HYPK (10 nM). GraphPad
Prism, version 5.01, was used for all data fitting to the Michaelis–Menten equation.
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3.4.9 HAT and NAT Radioactive Acetyltransferase Assays
SpNatA acetyltransferase assays were carried out under conditions previously
reported using 50 μM radiolabeled [14C]acetyl-CoA and 400 μM H4 peptide, which was
used for consistency with the hNatA assays.
hNatB (25 nM) acetyltransferase assays were carried out in 25 mM HEPES 7.5 200
mM NaCl using 400 μM each of actin peptide and [14C]acetyl-CoA in a 50 µl reaction
volume for 20 min at 25°C.
hNatD (225 nM) acetyltransferase assays were carried out in 25 mM HEPES 7 100
mM NaCl using 60 μM H4 peptide and 100 μM [14C]acetyl-CoA in a 50 µl reaction volume
for 15 min at 25°C.
hNaa50 (300 nM) acetyltransferase assays were carried out in 100 mM HEPES, pH
8.0, 50 mM NaCl 2 mg/ml BSA using 800 μM MLG peptide and 100 μM [14C]acetyl-CoA
in a 50 µl reaction volume for 25 min at 25°C.
hNatF (1 μM) acetyltransferase assays were carried out in 50 mM HEPES 7.5 100
mM NaCl using 60 μM MLG- peptide and 100 μM [14C]acetyl-CoA in a 50 µl reaction
volume for 15 min at 50°C.
hMOF (50 nM) acetyltransferase assays were carried out in 40 mM Tris 8.0 100
mM NaCl 800 μM cysteine 0.25 mg/ml using 400 μM H4 peptide and 50 μM [14C]acetylCoA in a 50 µl reaction volume for 60 min at 25°C.
hPCAF (500 nM) acetyltransferase assays were carried out in 100 mM HEPES, pH
8.0, 50 mM NaCl 2 mg/ml BSA using 400 μM H4 peptide and 50 μM [14C]acetyl-CoA in
a 50 µl reaction volume for 45 min at 25°C.
All HAT and NAT reactions above were performed in the presence and absence 5
μM WT MBP-HYPK and quenched, as previously described in Section 2.4.4.
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3.4.10 IC50 Assays
hNatA IC50 assays were performed under the same reaction conditions described
above, except substrates H4 peptide and radiolabeled [14C]acetyl-CoA were both set at a
constant sub-saturating concentration of 50 μM. To evaluate HYPK protein-induced
inhibition, 6xHis-hNatA was incubated with various concentrations of MBP-HYPK (660
pM-38 nM for ~15 minutes at room temperature). To evaluate the ability of a peptide of
HYPK35-48 to inhibit hNatA, hNatA was incubated with concentrations of HYPK peptide
or a non-specific gag peptide (16 μM-2 mM) for 1 hr. at room temperature. The reactions
were initiated by addition of [14C]acetyl-CoA and proceeded as detailed above. Reactions
were performed in triplicate and converted to molar units using a standard curve. The
results were normalized using the reaction lacking MBP-HYPK. An IC50 was calculated
using a log (inhibitor) vs. response fit on Prism 5.0. Error bars correspond to the SEM of
each point.
3.4.11 Generation of a Noncompetitive Tight-Binding (Morrison) Fit
In order to calculate the inhibition constant (Ki) of the hNatA-HYPK interaction (in
Figure 20E), we fit the data generated from the IC50 assays using a noncompetitive tightbinding (Morrison Fit) model represented by the following equation,
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[ E ]tot = Total active enzyme concentration
[ I ]tot = Concentration of HYPK
KM =

Peptide Michaelis-Menten Constant

[ S ] = Concentration of peptide
The Ki was calculated using GraphPad Prism 5.0, where the following parameters
were fixed, β = 0.081, KM = 30x103 nM, and [S]= 50 x103 nM.
3.4.12 Differential Scanning Calorimetry (DSC)
Wild-type binary 6xHis-tagged hNatA and ternary 6xHis-tagged hNatA/HYPK
construct samples were purified as described above in Section 3.4.4. Samples were
prepared and characterized using DSC as described in Section 2.4.5. DSC scans of binary
hNatA and ternary hNatA/HYPK samples were performed at concentrations of 7-8 µM and
6-8 µM, respectively. DSC runs were analyzed and visualized as described in Section
2.4.5.
3.4.13 MBP- and GST- Pull-Down Assays
6xHis-tagged proteins as well as MBP-tagged HYPK proteins were prepared as
described above. Free MBP was prepared as described for MBP-HYPK above. SpNatA,
hNaa10, as well as untagged and GST-tagged hNaa50 were prepared as previously
described (Liszczak et al. 2011, Liszczak et al. 2013, Magin et al. 2016). The pull-down
experiments represented in Figure 17B, Figure 19B, and Figure 21B were conducted by
incubating 2 µM MBP-tagged protein (or free MBP) with 6 µM bait (6xHis-tagged hNatA
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or hNaa10FL or SpNatA; or for the competition pull-down: 6xHis-tagged hNatA with or
without equimolar untagged hNaa50) in sizing buffer at 4°C for 30 min. Proteins were then
subjected to pull-down by incubation with amylose agarose resin (70µL slurry, New
England BioLabs) for 30 min. Resin was washed with 80 CV of sizing buffer before elution
of bound proteins by boiling resin in SDS gel-loading buffer.
The glutathione competition pull-down was performed by incubation of 2 µM GSTtagged protein with 6 µM 6xHis-tagged hNatA alone or in complex with an equimolar
concentration of HYPK∆1-33 in the same pull-down buffer as above for 30 min. Proteins
were then subjected to pull-down by incubation with glutathione agarose resin (70µL
slurry, Gold Biotechnology) for 30 min. Resin was washed with 80 CV of pull-down buffer
before elution of bound proteins by boiling resin in SDS gel-loading buffer.
Selection of the HYPK∆1-33 crystallization construct for the competition pull-down
was predicated on the need to decipher between HYPK from hNaa101-160; at full-length,
the HYPK migration distance is equal to that of hNaa101-160 by SDS-PAGE. This would
otherwise significantly impede visual inspection by SDS-PAGE gel.
Results of all pull-down assays were analyzed though visual inspection of input and
pull-down samples with 15% SDS-PAGE. Gels were stained using Coomassie Brilliant
Blue G-250.
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CHAPTER 4
Expanding the Biochemical Characterization of Naa10 and Naa15
Missense Mutations

Research performed on NatA missense mutations was performed in collaboration with Dr. Gholson
J. Lyon and Dr. Hanyin Cheng of the Stanley Institute for Cognitive Genomics at Cold Spring Harbor
Laboratory. The work is repeated here with permission from Hanyin, C.; Gottlieb, L.; et al… Marmorstein,
R.; Gholson, L. J., In Preparation.
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4.1 Introduction and Summary of Conclusions
The first developmental disorder described to be associated with an N-terminal
acetyltransferase (NAT), the X-linked Ogden Syndrome, arises from a (p.Ser37Pro)
mutation in the Naa10 (Ard1p in yeast) catalytic subunit of the NatA complex and leads to
infantile death in male carriers (Rope et al. 2011). Since its discovery, additional studies
have investigated the mechanism and the impact of the Naa10 (p.Ser37Pro) mutation (Van
Damme et al. 2014, Myklebust et al. 2015, Dorfel et al. 2017). Not surprisingly, other
NatA-related developmental disorders have since been reported, further underscoring the
importance of the role of NatA-mediated N-terminal acetylation in human development
(Naa et al. 2014, Casey et al. 2015, Popp et al. 2015, Saunier et al. 2016, Sidhu et al. 2017,
Stessman et al. 2017, Cheng, Dharmadhikari, et al. 2018, McTiernan et al. 2018, Nguyen,
Lee, et al. 2018, Stove et al. 2018, Takata et al. 2018, Zhao et al. 2018).
Here, we report the contribution of NatA missense mutations identified from
clinical presentations of Naa10-type disorders (Lyon 2017, Cheng, Gottlieb, et al. 2018) in
terms of their NatA stability as well as both NatA and NatA/HYPK complex enzymatic
activity. Together, these data create the basis for future work on NatA complex missense
mutations, which will serve as a tool for the study of NAT involvement in developmental
disorders.
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4.2 Results
4.2.1 Functional Characterization of Human NatA Missense Mutations – Naa10
To evaluate the effect of a selected group of human Naa10 missense mutations
identified in patients with developmental abnormalities (Figure 22A) (Lyon 2017, Cheng,
Gottlieb, et al. 2018), we overexpressed the heterodimeric mutant human NatA using the
same scheme developed for the WT human NatA. All of the mutants (D10G, L11R, S37P,
Y43S, I72T, R83C, A104D, and M147T) were soluble and were purified to homogeneity.

Figure 22 Annotated Structure of NatA/HYPK
(A) Missense variants (yellow; stick format) found in Naa10 (Purple) and
(B) Naa15 (dark teal) separately annotated on crystal structure of HYPK (light orange)-bound
NatA (PDB: 6C95) in cartoon with bound IP6 (brown; stick format).

We found that, except for R83C and M147T, mutations in the catalytic subunit
caused a significant decrease in enzymatic activity (Figure 23A). Consistent with previous
studies, the kinetic parameters measured for the S37P NatA complex were significantly
lower than WT, while the I72T only demonstrated a significant decrease in kinetic
parameters with respect to acetyl-CoA kcat (p=0.0130) and kcat/KM (p=0.0001) (Figure 24
and Table 7).
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Figure 23. Comparison of Activity and Thermal Stability of NatA Complex Missense
Mutants
Bar graph representing relative effect of a missense mutant compared to the heterodimeric
wild-type (WT) complex (-HYPK) on
(A) NatA complex activity and
(B) NatA/HYPK complex activity.
In both cases, activity was normalized with respect to WT NatA (-HYPK). Assays were
performed in triplicate; error bars S.D. Significance was calculated relative to WT using
Sidak’s multiple comparisons test.
(C) Differential scanning fluorimetry evaluation of WT and mutant NatA variants. Assays
performed in absence (black squares) and presence of acetyl-CoA (red circles). Assays
performed in triplicate with each replicate presented in a staggered scatter plot. Significance
was calculated with respect to the complex assayed in the absence of acetyl-CoA (black line)
or in the presence of acetyl-CoA-bound (red dotted line) using Sidak’s multiple comparisons
test.
**** p ≤0.00001; *** p≤0.0001; ** p ≤0.001; * p ≤0.05; ns p > 0.05
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Figure 24. Naa10 Mutant Enzyme Kinetics
Michaelis-Menten kinetics of WT and catalytic mutant NatA complexes with respect to
(A) H4
(B) acetyl-CoA
Assays performed in triplicate; error bars correspond to the S.D. for each point.

Table 7. Catalytic Parameters of Naa10 Mutant NatA Complexes
Mutant

Substrate

WT
S37P
****

H4

I72T
(ns)
WT
I72T

acetylCoA

kcat (min-1)

KM (µM)

kcat/KM (µM min-1)

310 ± 13.3

23 ± 3.3

13 ± 0.2

13 ± 0.9

1.9 ± 0.8

6.6 ± 0.4

280 ± 8.8

22 ± 2.3 (ns)

13 ± 0.1 (ns)

380 ± 24

29 ± 4.5

13 ± 0.2

310 ± 14 *

21 ± 2.5 (ns)

15 ± 0.1 ***

**** p ≤0.00001; *** p ≤0.0001; ** p ≤0.001; * p ≤0.05; ns p >0.05

Particularly, the activity of residues that make important contributions to the
integrity of the fold of the catalytic subunit resulted in the largest decrease in activity
(D10G, S37P, and A104D). The mutations likely alter numerous interactions including
the loss of hydrogen bond interactions and the perturbation of hydrophobic pockets.
Similarly, L11R, Y43S, and I72T likely promote changes in the hydrophobic surfaces that
they occupy, but they do not promote larger-scale structural changes that would impede Nterminal acetyltransferase activity. For example, while bulky, the L11R mutation can
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occupy other rotameric positions, allowing for the accommodation of its long aliphatic
chain so that it may find a favorable orientation. M147T, on the other hand, does not appear
to have any effect on NatA catalytic activity. By contrast, R83C appears to enhance NatA
activity. The mutation may promote the formation of a disulfide bond with Naa15-C322,
which could allow for improved positioning of acetyl-CoA for catalysis. Interestingly,
previous studies with monomeric human Naa10 have demonstrated that Naa10R83C has a
diminished catalytic capacity (Sidhu et al. 2017), which is consistent with our findings
indicating that in the absence of Naa15, Naa10R83C would no longer benefit from the
catalytic stabilization provided by Naa10R83C-Naa15C322 disulfide bond formation.
We were surprised to find that when we supplemented the NatA mutant reactions
with HYPK and re-evaluated their enzymatic activities, HYPK-mediated inhibition of
wild-type NatA activity was potentiated, decreased or nullified depending on the specific
mutant (Figure 23B). Interestingly, M147T, which had no effect in the heterodimeric state,
significantly decreased NatA activity upon addition of HYPK. D10G, Y43S, I72T, and
A104D also appeared to sensitize NatA to HYPK-mediated inhibition while L11R, S37P,
and R83C did not have a significant effect. In WT, the Naa15 a26-44 helical stalk serves
as the primary point of tight-binding for the Naa15-HYPK interaction. It is possible that
L11R and S37P are stabilized in the HYPK-bound complex relative to other mutants due
to packing-induced stabilization between the Naa15 helical stalk and either Naa10 a1
(L11R) or Naa10 a2 (S37P) helices. In contrast, HYPK binding nullified the enhancing
effects of R83C due to the HYPK-induced conformational changes in the acetyl-CoA
binding pocket.
Next, we compared the thermostability of apo heterodimeric NatA complexes with
mutant heterodimeric complexes in the absence and presence of its co-factor, acetyl-CoA
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(Figure 23C). We found that all of the mutants, except I72T, R83C, and M147T, were
destabilized in the absence of co-factor when compared to WT. By contrast, all mutants,
except I72T, were destabilized in the presence of acetyl-CoA with respect to WT. These
results indicate that the mutations are overall destabilizing for the heterodimeric complex,
where mutations that destabilize the GNAT fold – such as S37P, D10G, L11R, Y43S, and
A104D – reduce the stability of the complex in the absence as well as the presence of
acetyl-CoA. On the other hand, the complex may experience a minor stabilization by the
apo I72T because the mutation promotes the compaction of the hydrophobic pocket
between the Naa10 b4-strand and a3 helix. The stabilization of the R83C mutant complex
arises from the formation of a disulfide bond with Naa15 C322. By contrast, the R83C
mutant complex likely no longer benefits from the acetyl-CoA stabilizing effects due to the
loss of electrostatic interaction between the positively charged Arg83 side chain and the
negatively charged phosphodiester acetyl-CoA backbone. Similarly, M147T diminishes
the packing between the a4 helix and b7-strand, diminishing the stabilizing hydrophobic
packing effects of acetyl-CoA binding.
4.2.2 Functional Characterization of Human NatA Missense Mutations – Naa15
In order to evaluate the effect of the missense mutations found in the human Naa15
auxiliary subunit, we overexpressed the heterodimeric mutant human NatA using the same
scheme developed for the WT human NatA. With the exception of K450E, all of the
mutants (D112N, K338N, A475V, C484R, and L814P) were soluble and were purified to
homogeneity (Figure 25).

We found that K450E appeared to disrupt the NatA

heterodimeric complex, causing Naa15K450E to elute throughout the S200 column rather
than as a single peak (Figure 25A and B). Since K450 makes important interactions with
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the structural IP6 molecule, we reasoned that K450E would result in the loss of a hydrogen
bond as well as introduce a charge-charge repulsion between the mutant residue and the
negatively charged IP6 phosphate moieties. Consistent with this possibility, we found that
we were able to rescue Naa10-Naa15 association and enzymatic activity when the complex
was prepared with 15 µM IP6 (Szwergold et al. 1987), suggesting that the KD for the IP6NatA complex interaction may be decreased in the K450E mutant (Figure 25A-E).
Consistent with the overall destabilization of the complex, due to an enduring chargecharge repulsion and the loss of a hydrogen bond interaction, we observed that the
additional IP6 did not improve the melting temperature of the Naa15K450E mutant complex
(Figure 25F).
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Figure 25. IP6 Partially Rescues Naa15K450E Complex Function
(A) S200 gel filtration chromatogram comparing WT (solid black line) and HIS-Naa101160/Naa15K450E (K450E) mutant prepared without (solid blue line) and with 15 μM IP6 (dotted
blue line).
(B) Corresponding SDS-PAGE gel to the WT S200 elution profile for A.
(C) Corresponding SDS-PAGE gel to the K450E complex –IP6 elution profile for A.
(D) Corresponding SDS-PAGE gel to the K450E complex +IP6 elution profile for A.
(E) Bar graph representing relative effect of K450E (cyan) variant with respect to the
heterodimeric WT (black) complex on NatA complex activity, when prepared without (Apo) or
with IP6 (+IP6), as well NatA/HYPK complex (+IP6/HYPK) activity.
Activity was normalized with respect to WT NatA (Apo). Assays were performed in triplicate;
error bars S.D. Significance was calculated relative to WT using Sidak’s multiple comparisons
test.
(F) Differential scanning fluorimetry (DSF) evaluation of WT and K450E. K450E was
evaluated in the absence (-IP6) and presence of IP6 (+IP6). Both WT and K450E DSF assays
were performed in absence (black squares) and presence of acetyl-CoA (red circles). Assays
were performed in triplicate with each replicate presented in a staggered scatter plot.
Significance was calculated either with respect to the WT in the absence of acetyl-CoA (black
line) or in the presence of acetyl-CoA (red dotted line) using Sidak’s multiple comparisons test.
**** p ≤0.00001; *** p ≤0.0001; ** p ≤0.001; * p ≤0.05; ns p >0.05
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In order to understand how the other Naa15 mutants impacted NatA complex
activity, we characterized the overall effect of the mutant on NatA activity in the absence
and presence of HYPK (Figure 23A and B). We found that D112N and K338N both did
not significantly impact N-terminal acetyltransferase activity, likely due to the role and
position of D112 as a surface residue and K338N as a residue that is distantly located from
the Naa10-Naa15 interface (Figure 22A). Surprisingly, D112N and K338N also appeared
to stabilize the complex with respect to WT, regardless of acetyl-CoA (Figure 23C).
K338N, for example, may serve to form new hydrogen bond interactions, which may
stabilize the complex. A475V, C484R, and L814P all impact to the stability of the Naa10Naa15 interface through the stalk of helices (a26-45), depending on whether or not HYPK
is bound to the mutant complex. As a heterodimeric complex, C484R results in a
significantly reduction in NatA activity due the inherent steric bulk of the Arg side chain.
In the case of A475V, the Val side chain, while larger than the wild-type Ala residue, likely
contributes only enough to a small shift in the Naa15 a26 helix packing against the Naa10
a1 and a2 helices, shifting the helices so that the complex catalyzes activity less efficiently.
These mutant-induced steric shifts, however, are nullified upon HYPK-binding, likely due
to the stabilizing effect of HYPKUBA (C-terminal) binding to the Naa15 metazoan-specific
C-terminus. Although A475V and C484R are located in the same area of the Naa15 helical
stalk, the mutations have different effects on the thermostability of the NatA complex. This
difference likely arises from the positioning and identity of the mutations: they are on
opposite ends of the same a26 helix and are steric opposites. In the case of C484R, the
bulky Arg mutation in Naa15 a26 and pointing near the Naa10 a1/a2 helices potentially
pushes these Naa10 and Naa15 regions away from each other, resulting in a diminished
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Naa10-Naa15 contact area. The Val mutation, A475V, likely minimally perturbs the
Naa15 a26 helix so that it may pack more closely with the Naa10 a1/a2 helices. A larger
residue in this position, however, would likely lead to a similar effect that is observed with
C484R. In contrast, L814P has no effect on NatA complex activity unless HYPK is bound,
likely due to the steric restraints generated by a Pro mutation, reducing HYPK binding
integrity and, therefore, the inhibitory capacity of the interaction. Unsurprisingly the L814P
mutant reduces the thermostability of the complex, regardless of the binding of acetyl-CoA.
This data is consistent with a model where the L814P mutation results in a dramatic
reduction in the dynamics of the Naa15 a26-45 helical stalk that is necessary for HYPK
binding as well as tight packing with the Naa10 catalytic subunit.
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4.3 Discussion and Future Directions
Previous studies describing missense mutations in human NatA complex subunits
have been limited. Reports have solely focused on the effects of missense mutations on the
monomeric human Naa10 catalytic subunit, or used insufficient systems to study mutant
NatA subunits, including using yeast model systems or solubilizing maltose binding
protein (MBP)-tagged recombinant protein expressed in E. coli cells (Rope et al. 2011, Van
Damme et al. 2014, Casey et al. 2015, Popp et al. 2015, Saunier et al. 2016, Dorfel et al.
2017, McTiernan et al. 2018, Stove et al. 2018). Furthermore, these studies have not
considered the mutagenic effects on the enzymatic activity of the HYPK-bound complex,
which, due to its nanomolar-level inhibition constant, we believe to be constitutively bound
to the human NatA complex (Gottlieb and Marmorstein 2018). In order to characterize
human missense mutations found in the Naa10 catalytic subunit as well as the Naa15
auxiliary subunit, we generated and purified mutant human NatA recombinant protein from
insect cells, which we used to carry out associated enzymatic assays, in the absence and
presence of HYPK, and thermostability assays, in the absence of acetyl coenzyme A.
Our findings demonstrate that the severity of the missense mutations in the human
Naa10 catalytic subunit can be classified based on the impact on the integrity of the GNAT
fold. D10G, S37P, and A104D can be classified in this way. These findings are consistent
with previous reports that demonstrate that S37P presents as a fatal X-linked disorder in
infantile male individuals (Rope et al. 2011, Myklebust et al. 2015). Based on this data,
we expect that A104D and, particularly, D10G would confer equally severe phenotypes.
However, it must be noted that the mutations were not studied in the context of the
monomeric Naa10 catalytic subunit. Other studies have analyzed the effect of some of the
mutations on the monomeric Naa10 (Rope et al. 2011, Casey et al. 2015, McTiernan et al.
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2018). We anticipate that additional studies of the identified mutations will be performed
in the context of the monomeric catalytic subunit.
Previous studies have described the effect of truncating mutations on human Naa15
and, as a result, the human NatA complex (Cheng, Dharmadhikari, et al. 2018). Here, we
present a biochemical and enzymatic characterization of missense mutations in the Naa15
auxiliary subunit in the context of the NatA complex. Overall, based on correlation with
the human NatA and NatA/HYPK structures, we conclude that many of the mutations
likely impact the integrity of the Naa10-Naa15 interaction or, as in the case of
NatA/HYPK, HYPK-Naa15 interaction. We were surprised that Naa15K450E maintained its
ability to bind IP6, but only in excess, likely due to a decreased KD of IP6-NatA association.
In the cell, we believe that limited IP6 will lead to the destabilization of NatA and possibly
NatA/HYPK complex formation, suggesting that IP6 binding may be impacted by IP6 flux.
In contrast, while Naa15 A475V was a minimally perturbing mutation, C484R likely alters
the Naa15-Naa10 interface. By deteriorating the integrity of the Naa10-Naa15 interface,
missense mutations likely lead to decreased enzymatic activity. On the other hand, we
were intrigued to find L814P diminished the ability of HYPK to inhibit NatA activity,
likely due to a change in the dynamics or stability of the NatA/HYPK complex.
A majority of the mutations associated with developmental disorders resulted in a
reduction of canonical N-terminal acetyltransferase activity. Future therapeutic avenues
could exploit compounds that might stabilize Naa10 or the Naa10-Naa15 interface within
the NatA complex. Due to the tight binding affinity of the NatA-HYPK complex, work
could also take the NatA/HYPK complex into consideration to improve the integrity of that
complex, when warranted. Taken together, the data we present here indicates there is a
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need for the investigation of the nuances of NatA regulation and dysregulation, both by
means of structural molecules such as inositol hexaphosphate, and via binding partners.
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4.4 Methods
4.4.1 Construction of E. coli Expression Vectors
A pET-m41 vector engineered to contain an N-terminally MBP-tagged human
HYPK was kindly donated to us by Thomas Arnesen (University of Bergen).
4.4.2 Construction of Baculoviruses
Studies were performed with a hNaa15 subunit that contained either an uncleavable
N-terminal 6xHis-tag.

Mutations of the human NatA complex were generated by

introduction of a mutation using Stratagene QuikChange protocol, with the exception of
Mutant Naa101-160/Y43S/Naa15 which was generated by and purchased from Biobasic.
Mutant and truncation constructs and the corresponding mutations introduced can be found
in Table 8.
Table 8. NatA Missense Mutant Constructs
NatA Construct
Naa101-160/D10G/Naa15
Naa101-160/L11R/Naa15
Naa101-160/S37P/Naa15
Naa101-160/Y43S/Naa15
Naa101-160/I72T/Naa15
Naa101-160/R83C/Naa15
Naa101-160/A104D/Naa15
Naa101-160/M147T/Naa15
Naa101-160/Naa15D112N
Naa101-160/Naa15K338N
Naa101-160/Naa15K450E
Naa101-160/Naa15A475V
Naa101-160/Naa15C484R
Naa101-160/Naa15L814P

Mutation
GGT
CGC
CCC
TCT
ACC
TGC
GAC
ACT
AAT
AAT
GAA
GTA
AGG
CCC

MBP-tagged full-length human HYPK was subcloned from the pET-m41
expression vector into a pFastBac 1 vector.
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For each of these constructs, a bacmid was generated by transposition into DH10
bac competent E. coli cells using the bac-to-bac system (Invitrogen). Spodoptera
frugiperda (Sf9) cells cultured in SFM II medium were transfected with the bacmid using
cellfectin reagent (Invitrogen). The resulting baculovirus was amplified until reaching a
high titer.
4.4.3 Expression and Purification of 6xHis-tagged Human NatA Mutant Constructs
Sf9 cells were grown to a density of 1x106 cells/ml and infected using the amplified
Naa101-160/Naa15 baculovirus to an MOI (multiplicity of infection) of ~1-2. The cells were
grown at 27°C and harvested 48 hours post-infection. All subsequent purification steps
were carried out at 4°C and as described for the WT hNatA in Section 2.4.2, with the
following exception. Lysis and purification of Naa101-160/Naa15K450E was performed in
the presence and absence of inositol hexaphosphate (IP6; Phytic acid sodium salt, SigmaAldrich) such that all buffers contained a final concentration of 15 μM IP6 and analyzed by
radioactive acetyltransferase assay.
4.4.4 Expression and Purification of MBP-tagged HYPK Constructs
MBP-tagged HYPK was expressed and purified as described in Section 3.4.4.
4.4.5 hNatA Radioactive Acetyltransferase Assays
hNatA acetyltransferase assays were carried out as described previously in Section
2.4.4. Naa101-160/Naa15K450E purified in the absence (-IP6) and presence of 15 μM (+IP6)
was utilized in the assay without additional IP6. In the case of the latter sample, this
resulted in a final concentration of ~1.5 μM IP6 after reaction setup.
Steady-state catalytic parameters of the mutant NatA complexes were determined
as described for WT in Section 2.4.4, where an H4 peptide Km was calculated for Naa10186

160/S37P/Naa15,

and Naa101-160/I72T/Naa15, while an acetyl-CoA Km value was only

determined for Naa101-160/I72T/Naa15. Fitting was performed as described for WT.
4.4.6 Thermal Stability Assays
Frozen aliquots of WT and mutant NatA proteins were thawed and diluted in size
exclusion buffer (25 mM HEPES, pH 7.0, 200 mM NaCl, 1 mM TCEP) to a final
concentration of ~0.94 μM (~0.13 mg mL−1). 16 μL was added to the selected wells of a
MicroAmp Optical 384 well plate (Applied Biosystems) to a final concentration of ~0.75
μM (~0.1 mg mL−1). Sypro Orange (5000x stock, ThermoFisher Scientific) was diluted
1:500 using size exclusion buffer, and 4 μL of that diluted stock was added to each well.
The plate was spun down and heated from 20 to 95 °C using a qPCR (ABI 7900 RealTime
PCR) with a 2% ramp rate. Fluorescent readings were recorded every 2 min. Following
signal normalization, melting curves were generated from these data and analyzed in
GraphPad Prism using a Boltzman sigmoidal analysis where analysis was restricted to
boundaries that included the transition of interest. The Tm reported corresponds to the
inflection point of the sigmoidal curve, which represents the temperature at which half of
the population of the protein is unfolded. The resulting Tm was plotted as a scatter plot of
each individual sample using GraphPad Prism. Naa101-160/Naa15K450E purified in the
absence (-IP6) and presence of 15 μM (+IP6) was utilized in the assay with additional IP6
to ensure a final concentration of 15 μM (+IP6) after sample setup.
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CHAPTER 5
Naa38p Enhances NatC Complex Activity
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5.1 Introduction and Summary of Conclusions
NatC was initially identified because it modifies gag, the major coat protein of the
L-A double-stranded RNA virus (Tercero et al. 1993, Polevoda and Sherman 2001). The
described NatC complex is the only NAT that contains two conserved obligate auxiliary
subunits for catalytic activity and substrate specificity in eukaryotes (Polevoda and
Sherman 2001, Aksnes et al. 2016). Together, the catalytic subunit, Naa30p (Mak3p), the
large regulatory subunit, Naa35p (Mak10p), and the small regulatory subunit, Naa38p
(Mak31p), acetylate proteins beginning with ML-, MI-, MW- or MF-. Yeast knockdown
of any of the three NatC subunits generated similar phenotypes, including the absence of
N-terminally acetylated NatC substrates. Notably, knockdown of the gene encoding
human Naa30 in A-431 cells (epidermoid carcinoma cell line) results in a significant
decrease in the detection of Naa35 and Naa38 proteins, indicating that the catalytic subunit
plays a role in the stabilization of both NatC auxiliary subunits. Knockdown of the the
gene encoding human Naa30 results in p53-dependent apoptosis, alters the subcellular
localization of the Arf-like GTP-ase, hArl8b, and disturbs both mitochondrial morphology
and Golgi apparatus integrity (Starheim et al. 2009, Van Damme et al. 2016, Starheim et
al. 2017). Similar to the NatA complex, deletion or mutation of a NatC complex subunit
such as, Naa38p, can lead to developmental delays and physical impairments (Zhao et al.
2016).
To date, the study of NatC has been limited in its scope, consisting mainly of
proteomic analyses and cell-based assays (Polevoda and Sherman 2001, Wenzlau et al.
2006, Starheim et al. 2009, Aksnes et al. 2013, Starheim et al. 2017). These studies have
shown that Naa38p is necessary for N-terminal acetylation of NatC substrates in vivo
(Polevoda and Sherman 2001). However, these studies have not developed a model for the
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contribution of Naa38p to NatC-mediated N-terminal acetylation activity. Here, we report
that, consistent with previous studies in vivo, the small auxiliary subunit, Naa38p, is
necessary for robust acetyltransferase activity. Furthermore, we demonstrate that both
NatC

complexes

–

binary

(ScNaa30p/ScNaa35p)

and

ternary

(ScNaa30p/ScNaa35p/ScNaa38p) – are stabilized by the binding of the signaling molecule,
inositol hexaphosphate (IP6). IP6 binding, however, only improves the catalytic activity of
the ternary complex.

Finally, we describe methodology developed towards the

crystallization and structural determination of the S. cerevisiae NatC binary and ternary
complexes.
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5.2 Results
5.2.1 NatC Requires Naa38p for Robust Enzymatic Activity
To determine the role of Naa38p in NatC-mediated N-terminal acetylation, we
overexpressed the minimal “binary” S. cerevisiae (Sc)NatC complex, corresponding to the
catalytic (ScNaa30p) and NatA-like auxiliary subunit (ScNaa35p) using E. coli. We also
co-expressed the “ternary” ScNatC complex (ScNaa30p/ScNaa35p/ScNaa38p) in E. coli
and purified both complexes to homogeneity. When we compared the two complexes by
a radioactive acetyltransferase assay, we were surprised to see that the binary complex had
minimal enzymatic activity while the activity of the ternary complex was enhanced (Figure
26), indicating that ScNaa38p plays a key role in ScNatC activity.

Figure 26. Naa38p Enhances NatC Enzymatic Activity
Radioactive acetyltransferase assay performed using an MLG- peptide substrate.

5.2.2 Inositol Hexaphosphate (IP6) and Naa38p are Required for Maximal NatC activity
It was suggested that, like the NatA complex, the NatC complex binds the signaling
molecular, inositol hexaphosphate (IP6) (Pham 2012). In the NatA complex, IP6 makes
interactions between the Naa10 and Naa15 subunits of the human NatA complex, acting as
a glue between the two subunits. In order to evaluate whether NatC does interact with IP6,
we measured the thermostability of the binary and ternary complexes in the absence and
presence of IP6, all in the presence of the acetyl-CoA co-factor using differential scanning
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fluorimetry (DSF).

Consistent with previous reports, the binary and ternary NatC

complexes were stabilized – 2.7°C and 1.9°C, respectively – upon incubation with IP6
(Figure 27A). Unlike the HYPK and the NatA complex, where HYPK-binding results in
a ~6°C stabilizing shift (Gottlieb and Marmorstein 2018), the regulatory ScNaa38p did not
appear to contribute a significant level of stability to the NatC complex. However,
incubation of IP6 only increased the enzymatic activity of the ternary ScNatC ~2-fold
(Figure 27B). Interestingly, we found that the ternary ScNatC complex was more resistant
to proteolytic degradation compared to the binary complex (Figure 27C), suggesting that
ScNaa38p induces a conformational change that does not confer improved thermostability.

Figure 27. IP6 Interacts with the NatC Complex
(A) Differential scanning fluorimetry (DSF) evaluation of the binary (black) and ternary (lilac)
ScNatC complexes in the absence (-IP6) and presence of IP6 (+IP6). Assays were performed in
triplicate with each replicate presented in a staggered scatter plot. Significance was calculated
using Sidak’s multiple comparisons test.
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**** p≤0.00001; *** p≤0.0001; ** p≤0.001; * p≤0.05; ns p>0.05
(B) Radioactive acetyltransferase assay evaluating the binary (black) and ternary (lilac) ScNatC
complexes in the absence (-IP6) and presence of IP6 (+IP6). Assays were performed using the
gag-peptide substrate. Significance was calculated using Sidak’s multiple comparisons test.
(C) Trypsin-mediated limited-proteolysis of the binary and ternary ScNatC complexes in the
presence of co-factors: IP6, CoA, and gag peptide. Samples were visualized using Coomassiestained SDS-PAGE gel.

5.2.3 Binary and Ternary NatC Crystallization Trials
In order to determine the molecular basis for NatC-mediated N-terminal
acetylation, we engineered constructs based on secondary structure, limited proteolysis,
and sequence conservation. This was accomplished through separate sequence alignment
of each of the subunits from various organism in tandem with secondary structure
predictions. From this, we identified regions of low conservation that were eligible for
truncation.

This yielded the following respective binary and ternary constructs:

ScNaa30p1-161/ScNaa35p19-733 and ScNaa30p1-161/ScNaa35p19-733/ScNaa38p1-70.

Both

constructs were bacterially overexpressed and purified to homogeneity. The ternary
complex, consistent with data above, was active (not shown).
Initial crystallization trials using the binary complex were largely unsuccessful
when incubating with acetyl-CoA alone. However, co-crystallization with IP6 yielded
crystals that diffracted after optimization to ~3.5 Å (Figure 28A). Efforts to find a solution
for the binary complex using molecular replacement using models of the NatA complex or
the NatB complex were unsuccessful, regardless of side-chain trimming and chain
truncation. Heavy metal soaking using methyl mercury resulted in diminished resolution
and data quality.
Initial crystallization trials using the ternary complex were fairly successful with
incubation with either acetyl-CoA or gag 7mer peptide and CoA (Figure 28B). Similar to
the binary complex, we attempted to co-crystallize the co-factor bound complexes with IP6,
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but it produced a predominance of clear crystallization screen drops, and yielded crystals
that were not reproducible. Diffraction studies of the ternary complex co-crystallized with
acetyl-CoA yielded data that was anisotropic. On the other hand, diffraction studies using
the ternary complex co-crystallized with peptide and CoA yielded diffraction to ~4.5Å.
We hypothesize that the conformation of the binary complex likely represents an
“inactivated” state, which may explain the failure to use molecular replacement to solve
the binary structure.

We reasoned that the ternary complex, however, exists in an

“activated” state, as demonstrated by enzymatic assays. With this in mind, we used a
trimmed human NatA starting model for solution of the ternary complex data with
molecular replacement. Indeed, Phenix generated a potential solution but the data appears
to be twinned.

Figure 28. NatC Complexes Crystals
(A) Binary ScNatC complex crystals prepared with acetyl-CoA and IP6.
(B) Ternary ScNatC complex crystals prepared with CoA and gag peptide.
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5.3 Discussion and Future Directions
Although many of the NATs have been characterized in terms of their biochemical,
enzymatic, and structural properties, the NatC complex has not yet been described. Here,
we report that activity of the NatC complex requires the presence of the Naa38p auxiliary
subunit and that, similar to the NatA complex, both the binary and ternary ScNatC
complexes binds to inositol hexaphosphate (IP6) to enhance their thermostability. By
contrast, the binding of IP6 to the NatC complex to only appears to impact the enzymatic
activity of the ternary complex, and not the binary complex.
In order to develop a better understanding of the NatC complex, it would be
beneficial to develop models to describe the binary and ternary complexes. Unfortunately,
structural studies to investigate the basis for the above observations have not yet been
successful. Future work could focus on the potential ternary complex solution and the
phasing of the binary complex using other mercury derivatives. While the ternary ScNatC
data is pseudomerohedrally twinned, the twin fraction is less than 0.5, suggesting the
potential for refinement (Dauter 2003). Alternatively, if this does not yield a successful
solution, co-crystallization with IP6 and MLG peptide-linked-CoA bisubstrate inhibitor
may yield new crystal hits. If a solution for the ternary complex cannot be determined,
crystallization of NatC from C. thermophilum could be considered. Advances in cryogenic
electron microscopy (Cryo-EM) have allowed for the solution of macromolecular
complexes at atomic resolution (Frank 2017, Herzik et al. 2017). Moreover, there was a
recent study demonstrating that solutions of sub-100-kDa proteins are possible at atomic
resolution (Herzik et al. 2018). Preliminary grids of the ScNatC binary and ternary
complexes show that they are homogeneous and clean (Figure 29A and B), indicating that
Cryo-EM would be possible. If an X-ray crystal structure of the NatC complex from S.
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cerevisiae NatC cannot be obtained, the human complex could be employed for structure
determination using cryo-EM. The additional mass of ~130 kDa for the human NatC
ternary complex would make a cryo-EM structure more feasible.

Figure 29. Negative Stain EM of NatC Complexes
Images of the (A) binary ScNatC and (B) ternary ScNatC complexes incubated with co-factors
(CoA, IP6, and gag peptide) using transmission electron microcopy (TEM). Bar, 500 nm.
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5.4 Methods
5.4.1 Construction of E. coli Expression Vectors
The full-length S. cerevisiae (Sc)Naa13 (733 residues) was engineered into MCSI
of a pETDUET vector containing a tobacco-etch virus (TEV) protease-cleavable 6xHistag and MCSII containing ScNaa30p (1-176). The full-length ScNaa38p (1-88) was
engineered into a pET DUET vector containing a TEV-cleavable STREP-tag.
Crystallization studies were performed using truncated constructs: ScNaa35p19-733,
ScNaa30p1-161, and ScNaa38p1-70.
5.4.2 Expression and Purification of S. cerevisiae Binary NatC Complex
(ScNaa30p/ScNaa35p)
The binary (ScNaa30p/ScNaa35p) NatC was expressed using ScarabXpress T7lac
(Scarab Genomics) E. coli cells, which were grown in terrific broth media (DOT Scientific)
at 37°C to an OD600 of ~0.9 and induced by addition of 0.5 mM IPTG at 17°C for 16 hr.
All subsequent purification steps were carried out at 4°C.

Cells were isolated by

centrifugation, lysed by sonication in lysis buffer containing 25 mM Tris, pH 8.0, 300 M
NaCl, 10 mM β-ME and 10 mg/mL PMSF. The lysate was clarified by centrifugation and
passed over nickel resin, which was subsequently washed with >20 CV of lysis buffer
supplemented with 25 mM imidazole. The protein was eluted in lysis buffer supplemented
with 200 mM imidazole by batch elution. The 6xHis-tag was cleaved overnight by addition
of 6xHis-tagged TEV-protease during dialysis into dialysis buffer containing 25 mM Tris,
pH 8.0, 300 mM NaCl, 5 mM Imidazole, 10 mM β-ME. This solution was passed through
an additional nickel column to remove TEV protease as well as any uncut binary ScNatC.
The resin was then washed with approximately 3 CV of dialysis buffer supplemented with
25 mM imidazole, which was pooled with the initial flowthrough. This solution was
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dialyzed into ion exchange buffer containing 25 mM HEPES, pH 7.5, 50 mM NaCl and 10
mM β-ME and loaded onto a 5 ml HiTrap SP ion exchange column. The protein was eluted
in the same buffer with a salt gradient (50–750 mM NaCl) over the course of 20 CV (080% Buffer B gradient). Peak fractions were pooled and concentrated (50-kDa
concentrator) and loaded onto a Superdex 200 Increase 10/300 GL gel filtration column
(GE Healthcare) in a buffer containing 25 mM HEPES pH 7.0, 200 mM NaCl and 1 mM
TCEP. This protein was concentrated to 4-5 mg/mL as measured by UV280 until use.
Truncated constructs were expressed and purified as described above.
5.4.3 Binary NatC Complex Crystallization
Binary ScNatC (~4.5 mg/ml) was incubated with acetyl-CoA (Sigma-Aldrich) at a
1:3 molar ratio and inositol hexaphosphate (IP6; Phytic acid sodium salt, Sigma-Aldrich)
at a 1:5 molar ratio. Crystals were obtained after ~1-2 days with hanging-drop vapor
diffusion at 20°C in a 500 μL well solution containing 8% tacsimate, pH 7 16% PEG (both
Hampton Research) at a drop ratio of 1:1 of protein:well solution. Continued growing and
reached maximum dimensions within ~1-2 weeks. All crystals were cryoprotected by
transferring them to their respective well solutions supplemented with 25% glycerol (EMD
Millipore) before being flash-frozen in liquid nitrogen. Data for the binary ScNatC
complex were collected at beamline 24ID-C at the Advanced Photon Source (Argonne
National Laboratory). For phasing, a total of 360 frames (1° per frame) were collected.
Data was processed using XDS (Kabsch 2010).
5.4.4 Expression and Purification of S. cerevisiae Ternary NatC Complex
(Naa30p/Naa35p/Naa38p)
The ternary (ScNaa30p/ScNaa35p/ScNaa38p) NatC was co-expressed using
ScarabXpress T7lac (Scarab Genomics) E. coli cells, which were grown in terrific broth
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media (DOT Scientific) at 37°C to an OD600 of ~0.9 and induced by addition of 0.5 mM
IPTG at 17°C for 16 hr. All subsequent purification steps were carried out at 4°C. Cells
were isolated by centrifugation, lysed by sonication in lysis buffer containing 25 mM Tris,
pH 8.0, 300 M NaCl, 10 mM β-ME and 10 mg/mL PMSF. The lysate was clarified by
centrifugation and passed over nickel resin, which was subsequently washed with >20 CV
of lysis buffer supplemented with 25 mM imidazole. The protein was eluted in lysis buffer
supplemented with 200 mM imidazole by batch elution. The 6xHis- and STREP-tags were
cleaved first by incubation at room temperature during a two-hour dialysis into dialysis
buffer containing 25 mM HEPES, pH 7.5, 50 mM NaCl, 10 mM β-ME, which was then
transferred for incubation overnight at 4°C. This solution loaded onto a 5 ml HiTrap SP
ion exchange column and was eluted in the same buffer with a salt gradient (50–750 mM
NaCl) over the course of 20 CV (0-80% Buffer B gradient). Peak fractions were pooled
and concentrated (100-kDa concentrator) and loaded onto a Superdex 200 Increase 10/300
GL gel filtration column (GE Healthcare) in a buffer containing 25 mM HEPES pH 7.0,
200 mM NaCl and 1 mM TCEP. This protein was concentrated to 4-5 mg/mL as measured
by UV280 until use. Truncated constructs were expressed and purified as described above.
5.4.5 Ternary NatC Complex Crystallization
Ternary ScNatC (~4 mg/ml) was incubated with CoA (Sigma-Aldrich) at a 1:3
molar ratio and a 7mer peptide (corresponding to the first 7 residues of the killer viral major
coat protein, gag: MLRFVTK) at a 1:5 molar ratio. Crystals were obtained after ~1-2 days
with hanging-drop vapor diffusion at 20°C in a 400 μL volume well solution containing
160 mM sodium malonate, pH 5.9 12% PEG (both Hampton Research) and 10 mM DTT
(GoldBio.com). A detergent screen (Hampton Research) revealed that crystals could be
improved when glyco-diosgenin was present as an additive in the drop at a ratio of
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2.5:1.2:0.3 of protein:well solution:additive.

Presently, the best crystals have been

obtained using several rounds of iterative streak-seeding. Although crystals initially
appeared within 2-5 days, crystals continued growing and reached maximum dimensions
within ~2-3 weeks. All crystals were cryoprotected by transferring them to their respective
well solutions supplemented with 25% glycerol (EMD Millipore) before being flash-frozen
in liquid nitrogen. Data for the ternary ScNatC complex were collected at beamline 24IDC at the Advanced Photon Source (Argonne National Laboratory). For phasing, a total of
180 frames (1° per frame) were collected. Data was processed using HKL-3000 (Minor et
al. 2006).
5.4.6 Negative Stain Electron Microscopy
Frozen aliquots of binary and ternary ScNatC proteins incubated with IP6 (3xmolarexcess), CoA (3xmolar-excess), and the gag peptide (5xmolar-excess) were thawed and
diluted in size exclusion buffer (25 mM HEPES, pH 7.0, 200 mM NaCl, 1 mM TCEP) to
a final concentration of 0.58 and 0.64 mg mL-l, respectively. Samples were prepared by
Xuepeng Wei using the same staining method outlined in Section A4.8. Samples were
visualized using a FEI Tecnai T12.
5.4.7 Radioactive Acetyltransferase Assays
An enzymatic time course assay was performed using either 100 nM ternary fulllength ScNatC complex or 500 nM binary full-length ScNatC complex in reaction buffer
(25 mM HEPES, pH 7.5 100 mM NaCl 1 mM DTT) containing a final concentration of
400

μM

each

of

substrate

peptide

(peptide

MLGPEGGRWGRPVGRRRRP) and [14C]acetyl-CoA.
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sequence

corresponding

to:

Reactions were quenched

following the same procedure outlined in Section 2.4.4 at the following time points: 1
minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, and 45 minutes.
Following optimization of reaction buffer conditions, the ScNatC acetyltransferase
assay performed to evaluate the impact of IP6 binding was carried out such that reactions
containing 10 nM of either binary ScNatC or ternary NatC and reaction buffer (50 mM
HEPES, pH 7.5, 150 mM NaCl) were incubated with or without 220 μM IP6 for 30 minutes
at room temperature. The final reaction contained a volume of 30 µl, 100 μM of the in vivo
substrate, gag, peptide (corresponding to the first 7 residues of the gag peptide with a
positively-charged polyArg tail: MLRFVTKRWGRPVGRRRRP), and [14C]acetyl-CoA,
which was used to initiate the reaction. The reaction was quenched after 12 minutes
following the same procedure outlined in Section 2.4.4.
5.4.8 Thermal Stability Assays
Frozen aliquots of binary and ternary ScNatC proteins were thawed and diluted in
size exclusion buffer (25 mM HEPES, pH 7.0, 200 mM NaCl, 1 mM TCEP) to a final
concentration of ~1.21 μM (~0.13 mg mL−1). 16 μL was added to the selected wells of a
MicroAmp Optical 384 well plate (Applied Biosystems) to a final concentration of ~0.96
μM (~0.1 mg mL−1). Sample prepared with IP6 were prepared with a final concentration
of 220 μM. Sypro Orange (5000x stock, ThermoFisher Scientific) was diluted 1:500 using
size exclusion buffer, and 4 μL of that diluted stock was added to each well. The plate was
spun down and heated from 20 to 95 °C using a qPCR (ABI 7900 RealTime PCR) with a
2% ramp rate. Fluorescent readings were recorded every 2 min. Following signal
normalization, melting curves were generated from these data and analyzed in GraphPad
Prism using a Boltzman sigmoidal analysis where analysis was restricted to boundaries that
included the transition of interest. The Tm reported corresponds to the inflection point of
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the sigmoidal curve, which represents the temperature at which half of the population of
the protein is unfolded. The resulting Tm was plotted as a scatter plot of each individual
sample using GraphPad Prism.
5.4.8 Limited Proteolysis of ScNatC Complexes
Frozen aliquots of binary and ternary ScNatC proteins (crystallization constructs)
were thawed, incubated for 30 minutes with co-factors (3-molar excess CoA, 5-molar
excess gag 7-mer peptide, and 5-molar excess IP6) following dilution in size exclusion
buffer (25 mM HEPES, pH 7.0, 200 mM NaCl, 1 mM TCEP) to a final concentration of 1
mg mL-1 protein. Trypsin digestion was performed at room temperature at the following
dilutions: 1:100; 1:1,000; and 1:10,000. Reactions were quenched after 1 hour 30 minutes
by the addition of SDS gel-loading buffer and boiling. Results were analyzed though visual
inspection with 15% SDS-PAGE. Following staining using Coomassie Brilliant Blue G250.
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Appendix: Molecular Role of HYPK and NatA-Mediated Cotranslational N-terminal Acetylation in Huntingtin (Htt) Aggregation

This research was performed in collaboration with Dr. Lin Guo of the University of Pennsylvania.
Dr. Guo assisted with the ThT assays and visualization by transmission electron microscopy.
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A1 Introduction and Summary of Conclusions
Although the autosomal neurodegenerative Huntington’s disease (HD) has been
studied intensely, the basis for HD pathology has remained elusive. Upon onset, HD
patients progressively develop dementia, involuntary movements, and psychiatric
disturbances (McFarland and Cha 2011). Primarily, disease pathogenesis occurs in the
basal ganglia and, particularly, within the caudate, putamen, and globus pallidus
(McFarland and Cha 2011, HDSA.org 2018). After diagnosis, HD patients typically live
10-25 years until they perish (Ferrante et al. 1987, HDSA.org 2018).
The trinucleotide-repeat-expanded Huntingtin (Htt) protein has been identified as a
key contributor to disease pathogenesis, but the mechanism for this is greatly debated.
However, studies have found that the presentation of 35≤ CAG repeats is penetrant
(McFarland and Cha 2011). Similar to other CAG (polyQ)-expansion neurodegenerative
disorders, HD is characterized by the development of intraneuronal inclusions (Sahoo et
al. 2016, Bauerlein et al. 2017, Juenemann et al. 2018). However, it is unclear if these
inclusion bodies to the cause of the disease or are a result of disease progression. Due to
this chicken-egg problem, researchers have looked to understand the function of wild-type
Htt and how a gain- and/or -loss of function may contribute to neuronal death. In an attempt
to understand HD pathogenesis, a study was conducted to investigate novel mutant-induced
binding partners for clues. This led to the discovery of the protein chaperone now named
Huntingtin Yeast Two-Hybrid Protein K (HYPK), which is described to co-localize with
the N-terminus of Htt as well as reduce aggregation in cell models upon overexpression
(Faber et al. 1998, Raychaudhuri, Sinha, et al. 2008, Arnesen et al. 2010, Raychaudhuri et
al. 2014, Choudhury and Bhattacharyya 2015).
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Previous studies have investigated the impact of a variety of post-translational
modifications on Htt aggregation on the N-terminal domain (N17; residues 1-17 preceding
the polyQ-tract) and other domains (Saudou and Humbert 2016, Ratovitski et al. 2017,
Xiang et al. 2018), including lysine acetylation (Jeong et al. 2009, Chaibva et al. 2016),
palmitoylation (Yanai et al. 2006), phosphorylation (Deguire et al. 2018), SUMOylation
(Steffan et al. 2004), and ubiquitination (Gong et al. 2012, Schipper-Krom et al. 2012,
Juenemann et al. 2015, Yin et al. 2015, Juenemann et al. 2018). However, both N-terminal
processing and, particularly, N-terminal acetylation have not yet been considered due to
the incorporation of N-terminal tags in order to solubilize the recombinant Htt species or
the inclusion of an N-terminal methionine in the preparation of synthetic Htt peptides.
N-terminal acetylation is a ubiquitous co- and post-translational mark that can be
found on ~80% of human proteins (Arnesen et al. 2009, Van Damme, Hole, et al. 2011).
This mark has broad implications in the regulation of cellular processes, such proteinprotein interactions, protein-membrane interactions or localization, etc. The metazoanconserved N-terminal acetyltransferases (NATs) are responsible for the transfer of the
acetyl- mark from acetyl coenzyme A to the target peptide N-terminus. To date, seven
NATs (NatA-F and H) have been identified in humans, each consisting of a catalytic
subunit (Naa10-Naa60, and Naa80, respectively) and potentially up to two auxiliary
subunits. These enzymes specifically target substrates based on the first two residues in
the N-terminus.

In the case of NatA, N-termini must have been processed by the

methionine aminopeptidase (MetAP) such that excision exposes a residue with a small
radius of gyration. A previous study demonstrated that knockdown of the Naa10 catalytic
subunit of the N-terminal acetyltransferase A (NatA) complex or its regulatory binding
partner, HYPK, resulted in an increase in Htt aggregation (Arnesen et al. 2010).
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The N-terminal sequence of Huntingtin (Htt) appears to play a role in its
aggregation, but the exact role is still being investigated (Arndt et al. 2015, Adegbuyiro et
al. 2017). On the other hand, multiple studies have described the acceleration of Htt
aggregation through N17 domain-promoted Htt Exon1 oligomerization followed by
polyQ-promoted aggregation (Jana et al. 2005, Tam et al. 2009, Hoffner and Djian 2015,
Sahoo et al. 2016) Interestingly, the N-terminus of Htt corresponds to a canonical NatA
complex substrate, ATLEK-.

More recently, both wild-type and mutant Htt were

confirmed be N-terminally processed to yield an acetylated N-terminus: Ac-ATLEK-,
which purified as a dimer and was able to form higher-order oligomers (Huang et al. 2015).
Based on these earlier studies, we set out to characterize the effect of NatA-mediated
acetylation on Htt aggregation and stability. Consistent with this, we confirmed that the
Htt N-terminus is an in vitro substrate for NatA. N-terminal acetylation of synthetic Nterminal peptides results in a reduction in random coil character and the enhancement in
a-helical content and, unexpectedly, the mark promotes aggregation of a non-pathogenic
25 polyQ N-terminal fragment. Furthermore, we have found that, although neither HYPK
nor the NatA/HYPK complex binds to either an unmodified or N-terminally acetylated
monomeric HttQ44 recombinant protein fragment, HYPK does appear to impede fibril
formation via an unknown mechanism. These studies represent the first model where Nterminal acetylation is necessary for the propagation of Htt protein aggregation and plays
a role in a neurodegenerative disease.
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A2 Results
A2.1 Development of Htt PolyQ N-terminal Fragment Constructs for in vitro Studies
In order to conduct in vitro experiments to study the biochemistry and biophysics
of Huntingtin (Htt) aggregation, we developed a recombinant Htt N-terminal construct that
would be soluble until proteolytic cleavage (Figure 30A).

The Htt fragment was

constructed to encode for the first 17 residues, either a 25Q tract or an expanded 44Q tract,
a tobacco etch virus (TEV)-cleavable small ubiquitin-like modifier (SUMO) tag, and a
6xHistidine-tag. PolyQ lengths were selected based on previous studies, which have
demonstrated that polyQ tracts ≥35 have a higher propensity to aggregate and penetrant
(Kar et al. 2011, Kar et al. 2013, Kuiper et al. 2017).

Figure 30. HttQ44-SUMO (HttQ44) Recombinant Protein
(A) Schematic representation of domain structure for C-terminally SUMO-tagged recombinant
HttQ44 used for in vitro studies. TEV cleavage site inserted between Q44 and SUMO tag for
promotion of aggregation via TEV-proteolysis.
(B) HttQ44 Superdex 75 Chromatogram.
(C) HttQ44 TEV cleavage depicted using western blot (left, polyQ antibody) and coomassiestained SDS-PAGE.

Similar recombinant construct strategies have been employed previously via the
fusion of a proteolytically cleavable solubilizing tag, such as glutathione-S-transferase
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(GST), maltose binding protein (MBP), SUMO or thioredoxin tags, to the N-terminus of
the Htt fragment (Scherzinger et al. 1999, Poirier et al. 2002, Kegel et al. 2005, Kegel et
al. 2009, Bugg et al. 2012, Pandey et al. 2018, Reif et al. 2018). However, these studies
are limited in their scope due to their neglect of Htt co- and post-translational N-terminal
processing and associated influences on Htt aggregation and biochemical properties.
In order to address this, we have purified HttQ44 to homogeneity (Figure 30B).
Using Edman degradation sequencing, we have confirmed that the N-terminus of the
HttQ44 construct has been processed such that the methionine has been hydrolyzed and the
alanine N-terminal residue is exposed. Furthermore, we have demonstrated that TEV may
be used to cleave the C-terminal SUMO tag from the HttQ44 construct (Figure 30C).
In order to generate N-terminally acetylated HttQ44 (Acetyl-HttQ44), we used an
in vitro radioactive N-terminal acetyltransferase assay to confirm that the human NatA can
target a Htt peptide substrate (Figure 31A). Based on this data and previous studies of Nterminally acetylated a-Synuclein (Kang et al. 2012, Bartels et al. 2014), we co-expressed
either HttQ44 with S. pombe NatA for the production of N-terminally acetylated protein,
which we purified to homogeneity and confirmed to be N-terminally acetylated using
Matrix-Assisted Laser Desorption/Ionization (MALDI) Mass Spectrometry (Figure 31B).
Based on the work conducted above, we also prepared and purified recombinant
HttQ25, with (Acetyl-HttQ25) and without the N-terminal acetyl mark, for parallel
aggregation studies (Figure 31C).
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Figure 31. Htt N-terminal Acetylation
(A) Radioactive acetyltransferase assay against H4, Htt, and gag (a cognate NatC complex
substrate) peptides performed using recombinant NatA and NatA/HYPK complexes.
(B) MALDI-TOF spectra of unmodified HttQ44-SUMO (annotated as HttQ44: blue) and Nterminally acetylated HttQ44 (annotated as Ac-HttQ44: red).
(C) Coomassie-stained SDS-PAGE gel showing purified unmodified and N-terminally (Nt-)
acetylated recombinant Htt25 and HttQ44 recombinant constructs.

A2.2 Monitoring HttQ44 Aggregation
In order to visualize the aggregation of recombinant HttQ44, we used transmission
electron microcopy (TEM). Consistent with previous studies, HttQ44 aggregates were
visible as early as 30 minutes (not shown) and fully formed after 24 hours (Figure 32A)
(Poirier et al. 2002, Hoop et al. 2016). Moreover, we found that co-incubation with 40 µM
MBP-tagged HYPK blocked the formation of mature fibrils. Instead, aggregates appeared
to be amorphous and short in morphology (Figure 32B), suggesting that HYPK interacts
with HttQ44 in order to inhibit fibrilization.

109

Figure 32. Monitoring Unmodified HttQ44 Aggregation
(A) Time course images of unmodified HttQ44 aggregation monitored at room temperature
using transmission electron microcopy (TEM). Corresponding time points indicated below
image. Bar, 500 nm.
(B) TEM images of HttQ44 incubated for 24 hours at room temperature without (left) and with
(right) HYPK. Bar, 500 nm.
(C) Thioflavin T (ThT) monitoring HttQ44 aggregation as a result of TEV-promoted SUMOtag cleavage at 37°C with orbital shaking.

The Thioflavin T fluorescence (ThT) assay has been used to detect amyloid fibrils
from a variety of neurodegenerative diseases, including Htt fibrils (Naika et al. 1989,
LeVine 1993, Poirier et al. 2002, Bartels et al. 2011, Gade Malmos et al. 2017). In order
to monitor the kinetics of HttQ44 aggregation, we implemented a plate-based ThT assay
where TEV-catalyzed cleavage of the SUMO-solubilizing tag would promote HttQ44
aggregation (Figure 32C). Unfortunately, the assay was not reproducible: we were
initially able to detect rapid aggregation while assays performed later yielded little to no
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ThT signal, suggesting an error with the set-up. Moreover, the initial results are not
characteristic of published ThT assays monitoring Htt aggregation; aggregation follows a
lag phase of an hour to several hours, depending on conditions, such as buffer, experimental
sequence, presence of seeds, and/or presence of membranes (Thakur et al. 2009, Chaibva
et al. 2016, Pandey et al. 2018). Future studies will require the optimization of this assay
or the use of another assay for monitoring aggregation.
A2.3 HYPK Does Not Bind Monomeric HttQ44 Directly in vitro
Previous studies have suggested that wild-type (WT) and mutant Htt interact
directly with the Htt-interacting protein, HYPK (Faber et al. 1998, Raychaudhuri, Sinha,
et al. 2008, Choudhury et al. 2012, Raychaudhuri et al. 2014, Ghosh et al. 2018b, Ghosh et
al. 2018a). In order to evaluate the ability of HttQ44 to make direct interactions with
HYPK, we performed an MBP pull-down assay in the absence and presence of human
NatA. We found that neither HYPK nor the NatA/HYPK complex pulled-down HttQ44
(Figure 33A) and that supplementation with the CoA product did not facilitate pull-down
with the NatA/HYPK complex. Moreover, we did not observe HttQ44 pull-down by MBPHYPK even after N-terminal acetylation by incubation with acetyl-CoA and a substoichiometric amount of human NatA (Figure 33B). This data is consistent with work
described by Arnesen and colleagues, which found that neither NatA nor HYPK co-localize
with Htt aggregates (Arnesen et al. 2010). Taken together, we were unable to demonstrate
that HYPK can directly interact with monomeric mutant Htt.
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Figure 33. MBP-HYPK Does Not Pull-Down Monomeric HttQ44
Coomassie-stained SDS-PAGE of
(A) MBP pull-down assay comparing the ability of unmodified monomeric HttQ44 to bind to
MBP-HYPK and the MBP-HYPK/NatA complex (in absence and presence of CoA).
(C) MBP pull-down assay comparing the ability of unmodified (-acetyl-CoA) and N-terminally
acetylated (+acetyl-CoA) monomeric HttQ44 bind to MBP-HYPK.

A2.4 N-terminal Acetylation Promotes Helical Htt Peptide Propensity
In order to probe the effect of N-terminal acetylation on the secondary structure of
the Htt N-terminus, we used circular dichroism (CD) spectroscopy to evaluate either
unmodified or N-terminally acetylated peptides corresponding to the first 7 (7mer; Htt2-8)
and 16 (16mer; Htt2-17) residues of the Htt N-terminus (after methionine excision). We
found that both unmodified Htt2-8 and Htt2-17 had random coil CD spectra (Figure 34A and
B). On the other hand, the N-terminally acetylated Htt2-8 (Ac-Htt2-8) only had a pronounced
a-helix (220 nm) signal, while the N-terminally acetylated Htt2-17 (Ac-Htt2-17) peptide
displayed a pronounced 220 nm and a reduced random coil (208 nm) signal (Figure 34A
and B). Similar studies using a-Synuclein have demonstrated that N-terminal acetylation
of α-Synuclein promotes the a-helical propensity of the α-Synuclein N-terminus,
particularly in the presence of membrane (Kang et al. 2012, Dikiy and Eliezer 2014).
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Figure 34. N-terminal Acetylation of Htt Peptides Promote a-Helicity
Circular Dichroism (CD) spectra of unmodified (black) and N-terminally acetylated (red)
(A) Htt2-8 peptide
(B) Htt2-17 peptide

A2.4 N-terminal Acetylation Increases Htt Aggregation Propensity
To determine the effect of NatA-mediated N-terminal acetylation on Htt
aggregation, we visualized HttQ25 and HttQ44 protein, unmodified (HttQ44) and Nterminally acetylated (Acetyl-HttQ44), using the same TEM assay described above
(Figure 35A and B). A time course of Acetyl-HttQ44 aggregation revealed that Nterminal acetylation displays similar aggregation kinetics to unmodified HttQ44.
Unexpectedly, we found that Acetyl-HttQ25 also produced visible fibrils with notably
longer extensions with higher curvature, while the unmodified HttQ25 exhibited minimal
fibril formation (Figure 35C and D). Interestingly, a few HD patients with polyQ tracts
featuring lengths between 29 and 34 have been reported, suggesting that, in addition to
polyQ length-dependency, there are likely additional mechanisms that influence HD
pathogenesis (“The Huntington’s Disease Collaborative Research Group” 1993,
Rubinsztein et al. 1996, Kenney et al. 2007). Although, it is necessary to perform an
aggregation kinetics assay, such as the ThT fluorescence assay, to confirm these
observations. Taken together, this data suggests that N-terminal acetylation functions as
an aggregation-promoting mark in Huntington’s Disease.
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Figure 35. N-terminal Aceylation Enhances HttQ25 Aggregation Propensity
TEM images of
(A) Recombinant N-terminally acetylated HttQ44 (Acetyl-HttQ44) time course at room
temperature. Corresponding time points indicated below image.
(B) Recombinant unmodified HttQ44 prior to and after 24-hour incubation at room temperature.
(C) Recombinant unmodified HttQ25 prior to and after 24-hour incubation at room temperature.
(D) Recombinant N-terminally acetylated HttQ25 (Acetyl-HttQ25) prior to and after 24-hour
incubation at room temperature.
Bar, 200 nm.

114

A3 Discussion and Future Directions
Earlier studies described a direct interaction between the Huntingtin (Htt) protein
and a protein named Htt Yeast two-hybrid Protein K or “HYPK” (Faber et al. 1998,
Raychaudhuri, Sinha, et al. 2008, Raychaudhuri et al. 2014, Choudhury and Bhattacharyya
2015). However, a dissociation constant for the interaction between Htt and HYPK has
not been reported (Ghosh et al. 2018b). Our studies demonstrate that monomeric Htt does
not interact directly with HYPK, which is consistent with a report by Arnesen and
colleagues demonstrating that Htt does not co-localize with HYPK (Arnesen et al. 2010).
Instead, we propose that Htt is an in vivo substrate of the NatA and NatA/HYPK
complexes, allowing for the nascent Htt N-terminus to come in proximity of HYPK during
co-translational NatA-mediated N-terminal acetylation. Indeed, yeast two-hybrid (Y2H)
assays are prone to false positive results (Serebriiskii et al. 2000) and have been able to
detect stable substrate-enzyme interactions (Vidal and Legrain 1999).

Perhaps

highlighting the importance of the Htt N-terminus and its potential mutant cellular
activities, all of the proteins identified in that same Htt Y2H assay only made interactions
with the N-terminus of mutant Htt (Faber et al. 1998).
Our studies demonstrate that N-terminal acetylation promotes Htt aggregation –
particularly with shorter polyQ-repeat tracts – likely via the formation of an
oligomerization-promoting N-terminal a-helix. Consistent with this, HYPK has been
found to be downregulated in both cell and animal models of HD, likely due to reduced
occupancy of the HYPK promoter by the impaired Heat-Shock Factor 1, and HYPK knockdown results in an increase in aggregation (Arnesen et al. 2010, Choudhury et al. 2012,
Das and Bhattacharyya 2014, Choudhury et al. 2016, Neueder et al. 2017). Interestingly,
a previous report found that loss of N-terminal acetylation of the yeast prion and amyloid
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of Sup35 protein, [PSI+], promotes the chaperone-mediate clearance of the prion (Pezza et
al. 2009, Holmes et al. 2014). In contrast, reports demonstrate that, although it also confers
an increased a-helical propensity, N-terminal acetylation of a-Synuclein plays a nuanced
role in its aggregation and Parkinson’s Disease (PD). In the case of WT a-Synuclein, Nterminal acetylation leads to a reduction in aggregation, while a-Synuclein featuring some
familial PD mutations enhances its aggregation kinetics (Bartels et al. 2014, Lima et al.
2018). Similar to Htt, studies of a-Synuclein did not consider the effects of N-terminal
acetylation on protein activities (Bartels et al. 2011, Moriarty et al. 2013, Bartels et al.
2014, Dikiy and Eliezer 2014, Fernandez and Lucas 2018b, Lima et al. 2018).
Additional studies are necessary to develop a model for N-terminal acetylation in
HD and Htt aggregation.

To that end, the effect of N-terminal acetylation on Htt

aggregation kinetics, could be determined either by ThT fluorescence assays, turbidity
assays, dot blot assays, or filter trap assays (Juenemann et al. 2015, Toro et al. 2015, Cariulo
et al. 2017) (Gade Malmos et al. 2017, Scior et al. 2018). Since these studies have been
performed in vitro, the biological significance of the described phenomenon could be
evaluated using cultured neurons and glial cells to perform uptake-induced aggregation
assays using pre-formed fibrils. Cell-based studies could also be employed to evaluate the
connection between HD and HYPK-mediated inhibition, where we could implement the
reduction of the NatA-HYPK interaction through the expression of a mutant NatA (Naa101161/Naa15L814P)

complex (mutant detailed in Section 4.2.2) in a HD-model immortal cell

line.
In order to determine the biochemical and molecular basis for NatA-mediated Nterminal acetylation of Htt, we could characterize the kinetic parameters of NatA and
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NatA/HYPK-mediated Htt N-terminal acetylation and determine the structure of the
NatA/Htt and NatA/HYPK/Htt complexes by X-ray crystallography. We have already
identified a condition from a screen for the co-crystallization of acetyl-Htt/CoA with
NatA/HYPK that yielded ~8Å diffraction which we can use as the basis for further
optimization. Taken together, the data presented suggests that HYPK-downregulation and,
by consequence, N-terminal acetylation plays a role in HD pathogenesis. These studies
represent the first link between N-terminal acetylation and the promotion of a
neurodegenerative disease. The reported data and future work will provide the basis for
further investigation into the basis for NatA-involvement in HD, including the
identification of a potential therapeutic target.

117

A4 Methods
A4.1 Construction of E. coli Expression Vectors
Sequence encoding for the exon1 of the human Huntingtin (Htt) protein, which
consists of the N-terminal 17 residues and a 44-polyglutamine (polyQ) repeat, was
engineered into pET DUET vector and a pRSF vector both with a tobacco-etch virus (TEV)
protease-cleavable C-terminal SUMO tag, followed by a 6xHis-tag. A similar construct
containing a 25-polyQ tract was only engineered into the pRSF vector. The TEV cleavage
site and SUMO-tag are bridged by a four Gly-Ser (GS)-linker. The full-length S. pombe
(Sp)Naa15 (729 residues) was engineered into MCSI of a pET DUET vector containing a
TEV protease-cleavable 6XHis-tag with MCSII containing Naa10 (1-156) to co-express
the heterodimeric SpNatA complex with Htt recombinant constructs. Genes encoding the
HttQ25 and HttQ44 constructs described above were synthesized by Biobasic.
A4.2 Expression and purification of Htt proteins
HttQ25-(GS)4-SUMO-6xHis

and

HttQ44-(GS)4-SUMO-6xHis

were

both

expressed using BL21(DE3) pLysS cells (Millipore), which were grown in LB media
(Millipore) at 37°C to an OD600 of ~0.5-0.6 and induced by addition of 0.5 mM IPTG at
16°C for 16 hr. All subsequent purification steps were carried out at 4°C. Cells were
isolated by centrifugation, lysed by sonication in lysis buffer containing 25 mM Tris, pH
8.0, 150 M NaCl, 10 mM β-ME and 10 mg/mL PMSF and DNAse. The lysate was clarified
by centrifugation and passed over nickel resin, which was subsequently washed with >20
CV of lysis buffer supplemented with 25 mM imidazole. The protein was eluted in lysis
buffer supplemented with 200 mM imidazole by batch elution. The 6xHis-tag was cleaved
overnight by addition of 6xHis-tagged Ulp1-protease during dialysis into dialysis buffer
containing 25 mM Tris, pH 8.0, 150 mM NaCl,10 mM β-ME. This solution was passed
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through an additional nickel column to remove Ulp1-protease as well as any uncut Htt and
SUMO protein. This solution was loaded onto a 5 ml HiTrap Q ion exchange column. The
protein was eluted in the same buffer with a salt gradient (150–750 mM NaCl) over the
course of 18 CV (0-80% Buffer B gradient). Peak fractions were pooled and concentrated
(10-kDa concentrator) and loaded onto a Superdex 75 gel filtration column (GE
Healthcare) in a buffer containing 25 mM HEPES pH 7.0, 200 mM NaCl and 1 mM TCEP.
This protein was concentrated to 1 mg/mL as measured by UV280 until use. Prior to each
study, samples were thawed and spin filtered to remove aggregates.
A4.3 Western Blot Analysis
SUMO-tag cleavage was performed overnight at room temperature such that the
recombinant Htt was at a final concentration of 1.2 mg/mL and TEV was at a final
concentration of 0.24 mg/mL in sizing buffer. The reaction was quenched using 2X SDS
loading dye followed by boiling. 15 µL of sample was loaded onto a 15% acrylamide gel
analyzed by western blot using a 1:1,000 dilution of the primary antibody in 5% non-fat
milk, a mouse-derived monoclonal anti-polyQ (Sigma-Aldrich), and a 1:10,000 dilution of
the secondary antibody, sheep-derived HRP-linked whole Ab ECL Mouse IgG (GE
Healthcare), in 5% non-fat milk followed by a 30 second exposure.
A4.4 Edman Degradation
A 50 µM sample in sizing buffer was submitted to the Molecular Structure Facility
at the University of California, Davis Genome Center for Edman Sequencing. The
recombinant Htt N-terminus was subjected to sequencing using 5 cycles of analysis.
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A4.5 Radioactive acetylation of Htt Peptide
hNatA acetyltransferase assays were carried out as described in Section 2.4.4,
where reactions were incubated with 10 nM of 6xHis-tagged hNatA in a 30 µl reaction
volume containing 50 μM each of substrate peptide and [14C]acetyl-CoA (4 mCi/mmol;
PerkinElmer Life Sciences) for 12 min at 25°C. The substrate peptides (Genscript) used
in the assay corresponded either to one of three peptides: the first 7 residues of Htt followed
by a positively charged poly-Arginine track for electrostatic capture by the
phosphocellulose used in the assays, the first 19 residues of human H4 (Genscript), or a
control peptide with the first 7 residues of a non-NatA substrate (gag, a NatC substrate)
followed by a poly-Arginine track. The human H4 was selected in order to be consistent
with previous studies performed with the human NatA and NatA/HYPK complexes. Full
peptide

sequences

are:

ATLEKLMRWGRPVGRRRRP

(Htt),

SGRGKGGKGLGKGGAKRHR (H4), and MLRFVTKRWGRPVGRRRRP (gag).
A4.6 Expression and purification of N-terminally Acetylated HttQ44-(GS)4-SUMO
protein
Similar to studies performed with E. coli produced N-terminally acetylated aSynuclein (Kang et al. 2012, Bartels et al. 2014, Dikiy and Eliezer 2014), HttQ25-(GS)4SUMO-6xHis and HttQ44-(GS)4-SUMO-6xHis were both co-expressed with SpNatA
using BL21(DE3) pLysS cells (Millipore). Co-transformed cells were grown in LB media
(Millipore) at 37°C to an OD600 of ~0.5-0.6 and induced by addition of 0.5 mM IPTG at
16°C for 16 hr. All subsequent purification steps were carried out at 4°C and are identical
to the protocol implemented for the unmodified protein.
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A4.7 Matrix-Assisted Laser Desorption/Ionization (MALDI)
Unacetylated ( ~49 µM) and acetylated recombinant HttQ44 (~33 µM) in sizing
buffer were diluted 1:10 using milliQ water. The diluted sample was then mixed with
matrix consisting of saturated sinapic acid solution in a mixture of 30% Acetonitrile and
70% Milli-Q grade water containing 0.1% trifluoroacetic acid. MALDI mass spectra were
collected using Bruker Ultraflex III MALDI-TOF-TOF mass spectrometer (Billerica, MA).
with a molecular weight window of 5-21 kDa.
A4.8 Sample Preparation and Transmission Electron Microscopy (TEM) of Htt
Aggregates
Unmodified HttQ44-(GS)4-SUMO protein (10 µM) was allowed to aggregate by
incubation at room temperature overnight in sizing buffer.

In order to quench the

aggregation process, 5 µL of sample was spotted onto a formvar carbon-coated grid (EM
Sciences) and then stained with 2% uranyl acetate. Samples were collected every hour
over the course of 8 hours, with a final sample the next day after 24 hours following
initiation of the assay. Samples were then visualized using a Jeol-1010 transmission
electron microscope.
In order to evaluate the effect of HYPK on Htt aggregation, HttQ44-(GS)4-SUMO
protein (10 µM) was allowed to incubate with MBP-HYPK (72 µM) at room temperature
for 24 hours.
In order to evaluate the effect of N-terminal acetylation on Htt aggregation, Nterminally acetylated HttQ44-(GS)4-SUMO protein (10 µM) was allowed to aggregate by
incubation at room temperature overnight in sizing buffer. A time course was performed
following the same conditions described above. In parallel, umodified HttQ44-(GS)4121

SUMO protein (10 µM), and both unmodified (10 µM) and N-terminally acetylated
HttQ25-(GS)4-SUMO protein (8 µM) was allowed to aggregate by incubation at room
temperature overnight in sizing buffer. However, only a buffer sample along with an initial
sample (0 minutes) and a final (24-hour time point) sample were collected for analysis.
A4.9 Thioflavin-T Fluorescence Aggregation Assay
Aliquots of HttQ44-SUMO were thawed and spin-filtered to remove aggregates.
10 μM thioflavin-T (ThT, Abcam) was added to recombinant 16 μM HttQ44-SUMO,
which was followed by the addition of tobacco etch virus (TEV) protease (5:1 molar ratio)
to initiate SUMO-tag cleavage. Aggregation was subsequently monitored was using
Thioflavin fluorescent where every 2 min at 482 nm after excitation at 440 nm 110s orbital
shaking at an amplitude of 6 mm at 37 °C on a Tecan Safire II plate reader (Tecan USA)
over the course of 2.5 hours. Control reactions were monitored where ThT was added to a
solution containing either HttQ44-SUMO or TEV. A buffer control was also monitored.
ThT raw fluorescence values that were plotted as a function of time.
A4.10 Pull-Down Assays
Unmodified HttQ44-(GS)4-SUMO, 6xHis-tagged human NatA, and both free MBP
as well as MBP-tagged HYPK were all prepared as described above in Section 4.4.2,
Sections 2.4.3 and Section 3.4.4, respectively. The pull-down experiments represented in
Figure 33A and B were conducted by incubating 2 µM MBP-tagged protein (or free MBP)
with 6 µM bait (6xHis-NatA and/or unmodified HttQ44-(GS)4-SUMO) with 100 µM CoA
in sizing buffer at 4°C for 30 min. Proteins were then subjected to pull-down by incubation
with amylose agarose resin (70µL slurry, New England BioLabs) for 30 min. Resin was
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washed with 80 CV of sizing buffer before elution of bound proteins by a 15-minute
incubation with sizing buffer supplemented with 40 mM maltose.
In order to N-terminally acetylate Htt protein for pull-down analysis unmodified
HttQ44-(GS)4-SUMO was incubated overnight in sizing buffer at 4°C with 100 µM acetylCoA and 20 nM NatA. Sub-stoichiometric amount of human NatA were used in order to
maximize HttQ44-(GS)4-SUMO protein N-terminal acetylation while minimizing
visualization of the hNatA complex by SDS-PAGE gel. Unacetylated and acetylated
HttQ44-(GS)4-SUMO was then subjected to pull-down analysis by incubating 2 µM MBPtagged protein (or free MBP) with 6 µM bait (unmodified or acetylated HttQ44-(GS)4SUMO). The pull-down was then conducted following the same procedure outlined above.
Results of all pull-down assays were analyzed though visual inspection of input and
pull-down samples with 15% SDS-PAGE. Gels were stained using Coomassie Brilliant
Blue G-250.
A4.11 N-terminal Htt Peptide Synthesis
Peptides corresponding to the first 7 residues (ATLEKLM) and the first 16 residues
(ATLEKLMKAFESLKSF) of the N-terminal domain from Huntingtin, post-methionine
excision, were synthesized so that their C-termini were amidated and the N-terminus was
either left unmodified or N-terminally acetylated (Genscript).
A4.12 Circular Dichroism (CD) Spectroscopy
All spectroscopy was performed on samples in DBPS pH 7.4. In each scan, a
protein-absent reference was subtracted.
Circular Dichroism (CD) measurements were performed using an AVIV Circular
Dichroism Spectrometer Model 410. Isothermal wavelength scans were collected at 37°C.
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Quartz cuvettes having 1.0 cm path length were used for CD measurements. Htt 7mer
peptides were studied using a final concentration of 200 µM (unmodified) and 245 µM (Nterminally acetylated), while Htt 16mer peptides were studied using a final concentration
of 36 µM (unmodified) and 68 µM (N-terminally acetylated).
A4.13 Crystallization Screening of NatA/HYPK with CoA/Peptide
Ternary human NatA/HYPK (Naa101-160/Naa15/HYPK34-129) was purified as
described above in Section 3.4.4 (5.5 mg/ml) was incubated with CoA at a 1:3 molar ratio
and either unmodified 7mer Htt peptide or N-terminally acetylated Htt peptide at a 1:5
molar ratio. Initial crystals were obtained after 1-2 days with hanging-drop vapor diffusion
in a PEG/ION screen. While most of the initial identified hits were not amenable to
harvesting, there was one, PEG/ION G8 (2% tascimate pH 5.0; 100 mM sodium citrate
tribasic dihydrate pH 5.6; 16% PEG 3,350), which could be harvested using a
cryoprotectant containing the well solution supplemented by 20% glycerol.

Initial

diffraction studies were performed at the Highly Automated Macromolecular
Crystallography (AMX) Beamline at the National Synchrotron Light Source II (NSLS-II).
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